Document:

dxcm12312013ex1029

[*****] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS AND ASTERISKS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED INFORMATION.

Exhibit 10.29

NON-EXCLUSIVE DISTRIBUTION AGREEMENT

between DEXCOM, INC. and
Diabetes Specialty Center, LLC Dated Oct 12, 2009

[*****] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS AND ASTERISKS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED INFORMATION.

NON-EXCLUSIVE DISTRIBUTION AGREEMENT

THIS  NON-EXCLUSIVE  DISTRIBUTION   AGREEMENT   is  made  Oct  12,  2009  by  and between  DexCom,  Inc.,  a Delaware  corporation,  with  a  principle  place  of business  at 6340
Sequence  Drive, San Diego, California 92121 (the "Company")  and  Diabetes Specialty  Center,
LLC, a Utah corporation with a principle office at 3793 South State St. Salt Lake Citv,  UT 84115. The Company and the Distributor are referred to individually  as a "Party" and collectively as the "Parties".

The Parties hereby agree as follows:

1.        Definitions and Interpretation

1.1       Definitions

1.1.1     "Customer"   means  the  end-user   patient   to  which  the  Distributor   sells  the
Products;

1.1.2     "Effective  Date"  means  October   12,  2009,  being  the  date  upon   which  this
Agreement is deemed to commence;

		
	1.1.3 
	"Intellectual  Property Rights"  means  any  rights with respect to any intellectual property including but not limited to rights with respect to or under or pursuant to any patents, trademarks, copyrights, know-how  and trade secrets;

		
	1.1.4 
	"FOB Shipping Point" means freight on board the place from which the Company ships the Products to the Distributor;

		
	1.1.5 
	"Price" means the Price identified in Schedule 1, as amended from time to time in accordance with Section 2.2, below;

		
	1.1.6 
	"Products" means the Products identified in Schedule 1, as amended from time to time in accordance with Section 2.2, below; and

1.1.7     "Territory" means United States of America.

1.2  Interpretation

[*****] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS AND ASTERISKS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED INFORMATION.

		
	1.2.1 
	The words "include", "including"  and "in particular" shall be construed  as being by way of illustration only and shall not be construed as limiting the generality of any foregoing words.

1.2.2     Any  references   to  Recitals,   Section  or  Schedules  are  to  prov1s10ns of  and
Schedules to this Agreement.

		
	1.2.3 
	Section and paragraph headings  are inserted  for ease of reference only and shall not affect construction.

		
	1.2.3 
	Section and paragraph  headings  are inserted for ease of reference  only and shall not affect construction.

1.2.4   Words  denoting one  gender  include  all genders;  words  denoting  individuals  or persons  include  corporations   and  trusts  and  vice  versa;  words   denoting  the singular include the plural and vice versa; and words denoting the whole include a reference to any part thereof.

1.2.5   References to this Agreement mean this Agreement as the same may be amended, notated, modified or replaced from time to time with the agreement of the Parties.

2.     Appointment of Distributor, Additional Products and Relationship.

		
	2.1 
	The Company appoints the Distributor  to be its non-exclusive distributor  in the Territory for the Products and the Distributor  hereby accepts such appointment subject to the terms of  this  Agreement.     Distributor   agrees  that  it  shall  sell  products   only  to  end-user customers,  and  not to  other  distributors.     Distributor  also  agrees  it  may  market and promote Products to users for ambulatory (non-surgical) applications only.  Distributor shall not sell, market or promote  Products  for  use in critical care,  intensive  care or surgical settings.  The Company reserves  the right to appoint other non-exclusive  distributors and agents in the Territory for the Products.   The Company also reserves the right to sell the Products directly to Customers in the Territory.

		
	2.2 
	The Company  may from time  to time at its discretion  offer  additional  products to the Distributor for inclusion in this Agreement.  If the Distributor accepts those products, this Agreement  will be amended and signed by authorized representatives  of the Parties and thereafter such products shall be treated as the Products.   In addition,  the Company may amend the pricing set forth on Schedule 1.

3.     Relationship of Independent Contractor, Expenses, No Agencv or Authority.

		
	3.1 
	The  Distributor  is and shall  act as an independent  contractor,  and not as a partner, co­ venturer, agent, employee, franchisee  or representative of the Company.   No partnership, joint venture, agency or employment  is intended between Company and Distributor.

[*****] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS AND ASTERISKS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED INFORMATION.

		
	3.2 
	Except  as may be specifically  provided  for in this Agreement,  the Distributor  shall be responsible  for  any  and  all  expenses  incurred  by  Distributor  in  the  performance  of Distributor's duties under this Agreement.

		
	3.3 
	Nothing in this Agreement shall be construed  as giving Distributor authority to enter into obligations  on the Company's behalf or to act as the Company's  agent for any purpose; nor shall the Distributor hold itself out as having any such authority.

4.     Duties of Distributor

4.1     The Distributor hereby agrees:

		
	4.1.1 
	to use its best efforts to develop the market for the Products, promote the Products to Customers, physicians and certified diabetes educators, distribute and sell the Products to Customers throughout the Territory;

		
	4.1.2 
	to maintain a properly trained and equipped sales force for the Products, including but not limited to making its sales personnel available to the Company for training in the use and sale of the Products and coordination of sales efforts;

		
	4.1.3 
	to maintain  such  ordering,  billing  and filling  of customer  orders,  facilities  and personnel as the Company may reasonably specify;

4.1.4     to  follow   the  Company's  guidelines,   set  forth   below,  for   processing   new
Customers:

4.1.4.1 to  perform  an  investigation   of  benefits  and  relay  results  of  the  benefits investigation   to  the  Customer   within  48   hours   of  intake   of  each   new Customer;

4.1.4.2 to  collect  all  necessary  documentation   to  support  each  Customer's   claim within 7 business days;

4.1.4.3 to inform the Company  of each Customer  who ultimately  does not purchase the Company's Products due to inadequate insurance benefits;

4.1.4.4 to complete a prior authorization,  when required,  within  10 business days of performing the benefits investigation and collecting all required supporting documents;

4.1.4.5 to place purchase  order to ship Products to Customer within  3 business days of  receiving   prior  authorization   approval  from  the  Customer's  insurance company, or in the alternative, upon notice of a denial of a prior authorization request, to inform the Company within 24 hours of such denial;

4.1.5     to  follow  the  Company's  guidelines,  set  forth  below,  for  processing  existing

[*****] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS AND ASTERISKS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED INFORMATION.

Customers:

4.1.5.1 to  implement   an  active  call-back   campaign   to  procure   sensor   reorders, maintain customer  retention, and limit customer attrition;

4.1.5.2 to report on the status of the new and existing customers  order as reasonably requested by the Company;

4.1.6     to  forward all technical and repair service inquiries to the Company;

4.1.7     to promptly notify the Company of each new Customer  transaction  per Schedule
3;

		
	4.1.8 
	to implement and maintain a system, satisfactory to the Company, to identify the Distributor's  Customers  to which  each  batch of  Products  have  been  delivered ("batch" being the lot number marked by the Company  on each  unit container of the Products).  Distributor  shall maintain a tracking system sufficient  to allow the Distributor  the  ability   to  take  appropriate  corrective   action  in  the  market  if required;

4.1.9     to qualify as a Company supplier;

4.1.1 0  to obtain a prescription from a medical professional prior to the initial shipment of any Product to a new customer;

4.1.11  to comply with such good manufacturing and other practices as the Company may reasonably specify in respect of storage, handling, distribution and sale of the Products;

4.1.12  to leave in position and not cover, alter (unless authorized to do so in writing by the  Company),   remove   or  erase   any  notices,  warnings,   instructions,   marks (including without limitation,  notices that a patent, trademark, design or copyright or  other  Intellectual  Property  Right  relating  to  the  Products  is  owned  by  the Company or a third party) or any other writing which the Company  may place on or affix to the Products.   To maintain the integrity of the Products,  the Company has  approval  on  all  repackaging  configurations  the  Distributor  may  utilize in regard to the Products;

4.1.13  to not use any trade or service mark which is confusingly  similar to any trade or service mark used by the Company;

4.1.14  to not  infringe  upon  or  otherwise  use  any Intellectual  Property  Rights of  the
Company;

4.1.15  not to do anything to bring the Company or the Products into disrepute;

[*****] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS AND ASTERISKS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED INFORMATION.

4.1.16  to promptly  notify the Company of all incidents,  potential  events  or complaints relating  to  the Products,  and  to  comply  with  all  reasonable  directions  of  the Company,   whether   regarding   the  handling   of   specific   incidents,   events  or complaints in the Territory, or regarding the continued  sale of the Products in the Territory  in  the  light  of  any  other  incident,  event,  complaint  or    information otherwise reported to the Company;

4.1.17  to  ensure   that  it  and   its  employees   conform(s)   with  all  legislation,   rules, regulations and statutory  requirements existing in the Territory from time to time in connection with the Products;

4.1.18 to meet with representatives of the Company at least quarterly to discuss promotional programs and to implement such promotional programs as the Company may reasonably specify;

4.1.19 to provide advertising and sales representation for local and regional trade shows where the Distributor has representatives, and to provide an annual list of shows to be attended by the Distributor;

4.1.20 not to provide any wan-anty with respect to the Products other than the Company's warranty;

4.1.21 to provide the Company, from time to time upon request by the Company, with appropriate  credit   references  (other  manufacturers,  etc.)   with   whom  the Distributor has credit relationships in excess of $200,000 of purchasing activity per month.  If Distributor purchases in excess of $50,000 of Products per quarter, Distributor shall establish DexCom as the beneficiary of a 30 day irrevocable standby letter of credit in a reasonable amount determined by DexCom;

4.1.22 to obtain and maintain reasonable amounts of insurance to protect it and its employees and agents for loss or damage of inventory, property damage and other insurance which may be required in the Territory and to provide evidence of such insurance to the Company from time to time at the Company's request;

4.1.23  to appoint any sub-distributor or sub-agent only with the prior written approval of the Company;

4.1.24 to provide all reasonable assistance to the Company to ensure the successful performance of this Agreement;

4.1.25 to provide the Company with monthly forecasts by Product in accord::mce with requirements set forth in Schedule 4;

[*****] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS AND ASTERISKS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED INFORMATION.

4.1.26 to establish and maintain a tracking system in compliance with the Safe Medical Device Act and the FDA Regulation (21 CFR 821) as amended to enable the Products to be promptly located within commercial distribution.  The Distributor agrees to provide the Company with device tracking information, at such times as the Company may reasonably request, in order to demonstrate the effectiveness of the tracking systems.   The device tracking records shall not be discarded or destroyed without prior written consent from the Company;

4.1.27  to provide the Company with Product sales tracing reports, on up to a daily basis as reasonably requested by the Company, in the format set out on Schedule 3:

4.1.28  not to alter or damage any Products;

4.1.29  not to sell any Products  which are altered,  damaged,  or contaminated  or which have been removed from their original packaging; and

4.1.30  not to sell any Product where the shelf-life on the Product is less than the time of reasonable consumption  by the Customer, and in no instance to ship Product with a shelf-life of less than 2 months.

5.     Duties of the Company

5.1     The Company hereby agrees:

		
	5.1.1 
	to  provide   Distributor   and  Distributor's   Customers   technical   assistance  and support for the Products  via access to the Company's  technical services telephone line at such times as the Company shall determine in its sole discretion;

		
	5.1.2 
	to   attend   regional   sales   meetings   and   national   conventions   as  reasonably requested by the Distributor; and

		
	5.1.3 
	to provide training classes for the Distributor's sales and internal Product support personnel on the Products as requested by the Distributor and agreed to by the Company.

6.     Restrictions on Distributor

6.1     The Distributor hereby agrees:

6.1.1     to obtain Products and supplies related to the Products only from the Company;

		
	6.1.2 
	in relation to the Products,  not to seek Customers outside the Territory or establish any branch or maintain any distribution depot outside the Territory;

[*****] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS AND ASTERISKS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED INFORMATION.

		
	6.1.3 
	it  may  market  and  promote  Products  to  users  for  ambulatory  (non-surgical) applications only.  Distributor shall not sell, market or promote Products for use in critical care, intensive care or surgical settings.

7.     Prices and Terms

7.1       The  Prices for  the  Products  will  be as set  out  on Schedule  1.   Such  Prices  may  be increased from time to time by the Company.

		
	7.2 
	The Products will be supplied FOB Shipping Point freight prepaid.  Freight costs will be included on the invoice.

		
	7.3 
	All invoices submitted  by the Company to the Distributor  shall be payable  within [****] after the date of such invoice.  If the Distributor fails to pay or procure payment of the full amount  when due,  and without in  any manner  excusing  such  violation, the

Distributor agrees to pay the Company interest  at the greater  of:   (i) a rate of [****]  per month; or (ii) the highest rate legally permissible  on the amount (including interest) due and  owing to the Company,  from  the date  the  payment  is due.   The Distributor also agrees to pay all collection costs, expenses and reasonable attorney fees for collection of any amount due and unpaid.  Without prejudice to any of its other rights, the Company may withhold shipments  of the Products if the Distributor has not paid an invoice when due.

		
	7.4 
	The  Distributor shall  bear the cost of any sales,  excise or other  taxes imposed  by any governmental authority unless appropriate tax exemption certificate or resale certificate is provided to the Company prior to shipment.

7.5     The Distributor agrees to comply with Company's  standard ordering methods, set out on
Schedule 2.

		
	7.6 
	The Distributor shall establish  and maintain creditworthiness with the Company,  which shall be established prior to the effective date of this Agreement  in the sole judgment of the Company, based on the Company's  review of Distributor's credit references.

8.     Supply of Products

		
	8.1 
	Subject  to  availability,   the  Company  shall  use  its  reasonable   efforts  to  supply  the Distributor's  requirements  for the Products.   No order shall  be effective  until approved and accepted in writing by the Company.  The Company may, in its sole discretion, reject or cancel any order for any or no reason and the Company shall incur no liability of any kind for such action or for any delay or failure of delivery or performance.

		
	8.2 
	Nothing in this Agreement shall prevent the Company from selling or supplying Products to third parties in or outside the Territory.

[*****] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS AND ASTERISKS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED INFORMATION.

		
	8.3 
	The Company will provide free of charge Product literature  as reasonably  requested by Distributor.     If  the  Company  determines  that  the  Distributor's requests  for  Products literature   are  in   excess  of  Company 's   reasonable   capacity,   then   Company   and  the Distributor shall mutually agree upon a fee schedule for Product literature.

		
	8.4 
	The  Distributor  hereby  agrees  that  if  it  makes  reference  to  or  statements  about  the Products  in the Distributor's own catalogues,  promotional  literature,  advertisements  or the like:

		
	8.4.1 
	it will inform  the Company in advance and take such steps as the Company may reasonably  require  to ensure the accuracy  of any such  references  or statements; and

[*****] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS AND ASTERISKS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED INFORMATION.

		
	8.4.2 
	it will incorporate such references to the Company and to the Company's patents, trademarks,  copyrights  and  other  Intellectual  Property  Rights  as  the Company may reasonably require.

		
	8.5 
	Nothing in this Agreement shall require the Company to give the Distributor any right of priority over the Company's other distributors or customers.

		
	8.6 
	Nothing in this Agreement shall require the Distributor to give the Company any right of priority over the Distributor's other contracted vendors.

		
	8.7 
	Nothing in this Agreement shall prevent the Company from ceasing to make or sell all or any of the Products  at any time; or from modifying  or replacing  any of the Products at any time; or making or selling products which are competitive  with the Products; all with a 60 day written notice to the Distributor.

9.     Confidentiality

		
	9.1 
	Confidential  Information  shall mean all information  supplied  by one Party  to the other Party, or to which a Party has access including all written material, product samples, Specifications,   drawings,   designs,   plans,   layouts,   procedures,   computer   programs, models,   prototypes,   business   plans,   financial   information,   customer   lists   or  other information of any description belonging to a Party or in the other Party's possession.

		
	9.2 
	Each of the Parties shall keep secret and use only for the purposes of this Agreement all oral or written Confidential Information.

		
	9.3 
	The obligations of confidentiality  and non-use shall expire five (5) years from the date of termination or expiration of this Agreement, and without prejudice to the generality of the foregoing,   no  obligation   of  confidentiality   or  non-use   shall  apply  at  any  time  to information which:

9.3.1     is in the public domain at the time of disclosure;

		
	9.3.2 
	comes into the public domain, otherwise than by reason of the act or omission of the Party who receives the same (the "Recipient");

9.3.3     is supplied to the Recipient by a third party having a legal right to do so;

		
	9.3.4 
	can  be  proved  to  the  reasonable  satisfaction  of  the  other  Party  to  have  been developed independently  by the Recipient without resort to the disclosure; or

		
	9.3.5 
	which the Recipient  is obligated  to disclose  by law  or by any body having the force of law.

[*****] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS AND ASTERISKS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED INFORMATION.

9.4     The Company and  the Distributor  agree that it is for their mutual  benefit for  the other
Party to receive the Confidential Information, accordingly the Parties agree that it shall:

9.4.1    maintain  in  confidence  the  Confidential   Information   and  will  only  use  the information as required under this Agreement;

		
	9.4.2 
	not disclose such Confidential Information  to any third party who is not bound by this Agreement other than properly  authorized  officers, employees  or agents  of the Party who are required to receive the Confidential  Information  on a need-to­ know basis for implementing this Agreement;

9.4.3     not  copy  or  duplicate  or  in  any  way  reproduce  or  replicate  the  Confidential
Information except as needed to implement this Agreement; and

		
	9.4.4 
	without prejudice to the generality  of the foregoing, shall exercise  an equivalent degree of care in protecting the Confidential  Information as that which it uses to protect its own information of like sensitivity and importance.

10.      Health Insurance Portability and Accountability Act (HIPAA) Compliance.   The Parties   agree   to   comply   with   the  Health   Insurance   Portability   and   Accountability   Act ("HIPAA").   The Distributor agrees to keep any protected health information  including, but not limited  to, the identity  of the customers,  their  medical  records  and other  related  confidential medical information,  in confidence.   Distributor shall comply in all material respects with all applicable   Federal   and  local   laws  and  regulations   regarding   the  p1ivacy  of  individually identifiable  health infom1ation (including its collection,  use, storage, and disclosure), including, but not limited to, the Health Insurance Portability  and Accountability  Act of 1996 ("HIPAA") and the regulations  promulgated thereunder, as may be amended from time to time.  Distributor will use all reasonable efforts to protect the privacy and security of Patient Data and will require its business partners to do so also.

11.      Intellectual Property Rights

11.1     Nothing  in this Agreement  shall be construed  as giving  the Distributor  any license  or
1ight to any Intellectual Property Rights belonging to the Company.

		
	11.2 
	The Distributor  shall resell the Products  only in the original packaging  for the Products and  shall  not  alter such  packaging  or  labelling  without  the Company's  prior  written consent.

		
	11.3 
	The Distributor shall comply with all reasonable requests by the Company with regard to identification   of  the  Company's   Intellectual   Property   Rights   and  the  like   on  any promotional  material prepared by the Distributor in connection with the Products.

12.      Duration of Agreement

[*****] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS AND ASTERISKS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED INFORMATION.

		
	12.1 
	Subject to the following provisions, this Agreement shall be deemed to commence on the Effective Date and shall terminate on the second anniversary of the Effective Date (the "Term"),  provided that either Party may terminate this Agreement at any time upon [****]  prior written notice to the other Party.   The Parties may at any time agree in writing to extend the Term or to renew this Agreement.

		
	12.2 
	The Company may terminate this Agreement immediately,  by providing written notice to the Distributor, in the event of any of the following events:

12.2.1  the Distributor is in breach of this Agreement and has not remedied  such breach within [****]  of receiving written notice from the Company  to do so;

12.2.2  the effective control of the Distributor shall change; or

		
	12.2.3  the Distributor shall become insolvent or have a receiver appointed of its business or 
	go   into   liquidation    (except    for   the   purposes    of    amalgamation    or reorganization).

13.    Consequence of Termination

13.1     If for any reason this Agreement shall be terminated:

13.1.1  the Distributor will promptly pay all outstanding  unpaid invoices rendered by the Company  in respect  of the Products  which shall  become immediately  due  and payable by the Distributor, and in respect of Products ordered prior to termination but  for  which  an  invoice  has  not  been  submitted,   the  Distributor   shall  pay immediately upon submission of the invoice;
13.1.2  termination  or expiration  of this Agreement for whatever reason  shall not entitle the Distributor to any compensation or indemnity in respect of such termination or expiry except to the extent that the governing law of this Agreement  provides for such compensation or indemnity; and

13.1.3  the Distributor will, free of charge, return to the Company all tangible know-how and confidential information, promotional material, and all other literature and merchandise of any description relating to the Products or the Company's business and shall cease to use any of the Company's Intellectual Property Rights except as and to the extent necessary to sell any of the Products which the Distributor has in its inventory.

		
	13.2 
	Termination of this Agreement shall not prejudice the rights and remedies  of either Patty against the other in respect of any antecedent  claim or breach of this Agreement, except that neither Party shall be entitled to claim  damages against the other for termination of this Agreement  pursuant to Section 12. The provisions of Sections 3, 5, 8, 9, 11, 12, 13 and 16 shall survive the termination of this Agreement.

[*****] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS AND ASTERISKS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED INFORMATION.

14.    Indemnification

		
	14.1 
	Both parties to this Agreement shall indemnify,  defend and hold harmless  the other party from  and  against  all claims,  demands,  losses,  expenses  (including,  but  not limited  to attorney fees) and liability from:

14.1.1  losses relating to liability of the other party as an employer for claims by the other
party's  employees or agents; and

14.1.2  injury  to  persons  or  damage  to  property  caused   by  the  acts,   omissions or negligence of the other party or its agents in the sale, transportation,  possession or use of the Products.

		
	14.2 
	The Distributor shall indemnify, defend and hold harmless the Company from and against all claims, demands, losses, expenses (including, but not limited to attorney fees) and liability from  any claim  arising from  warranties  made by the Distributor  different from or in addition to those made in writing by the Company.

15.      Returned Products

Prior  authorization  from  the  Company  is  required  before  a  return  of  any  Product  will  be accepted.  Contact the Company's customer service at 877-339-2664.   The Company accepts no responsibility  for Product returned  without prior authorization.   The Company  will provide full credit  for  Product shipped  in Company  error,  damaged  or  defective  when shipped  including applicable  shipping charges.   No  partial  case quantities  will  be  accepted.    Any  unauthorized returned Product will be returned at the Distributor's expense.   The Company will also provide full credit for Product  shipped  in accordance  with its standard  30 day money  back guarantee. The Distributor shall not under any circumstances  receive returned  Products for placement into its inventory.

16.      Representations And Warranties

		
	16.1 
	Law, Licenses, and Permits.   Both parties to this Agreement  are in compliance  with any and all laws and regulations  governing the sale of the Products and have all licenses and permits  necessary   to  represent   the  Products   in   the  Territory.      Distributor  further represents and warrants that the solicitation and sale of Company's Products under this Agreement  will  not  violate  any  law  or  regulation,   including  any  law  or  regulation governing the sale of Products in the Territory.

		
	16.2 
	Organization/Power/Authority.  Distributor and the Company,  if other than  individuals, are duly organized  and existing  and in good  standing  under  the laws  of the state and country of their organization  and are entitled to own or lease their properties and to carry on their businesses as and in the places where such properties  are now owned, leased or operated, or such businesses are now conducted.  Both parties to this Agreement have full power and authority to provide  the services  specified herein  and all corporate  and other proceedings  necessary  to  be  taken by  both  parties  in  connection  with  the transactions provided for by this Agreement  and necessary to make the same effective have been duly and validly taken, and this Agreement  has been duly a

[*****] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS AND ASTERISKS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED INFORMATION.

nd validly executed  and delivered by  both  parties  and  constitutes   a  valid  and  binding   obligation   of  both  parties  in accordance with their terms subject to the laws regarding creditors’ rights, bankruptcy and general principles of equity.

16.3 Non-Breach. Etc.   The execution and delivery of this Agreement and the consummation
of the transactions  contemplated  hereby by both parties  to this Agreement  will not (a)violate or breach either party's Articles of Incorporation or Organization or Bylaws as applicable, (b) result in a breach of any of the terms or conditions of, or constitute a default   under,   any mortgage.   note,   bond,   indenture,   agreement.   license   or  other instrument or obligation to which either party is now a party or by which it or any of its properties or assets may be bound or affected, or (c) violate any order, writ, injunction or decree  of  any  court,  administrative  agency  or  governmental  body  in  any  respect,  the violation  or  breach  of  which  would  prevent     either  party  from consummating   the transactions  contemplated  herein  or  have  a  material  adverse  effect  on  the  business financial               or              otherwise               of              the              other               party.

		
	16.4 
	Consents. Distributor  is not and will not be required to give any notice to or obtain any consent from any person in connection with the execution and delivery of this Agreement or the consummation or performance of any of the transactions contemplated hereby.

17.     General Provisions

		
	17.1 
	Notice.  Any notice or other communication required or permitted to be given under this Agreement shall be properly served only if it is in writing addressed as set out below. Notice may be sent by any of the following methods: (ii) nationally recognized  overnight courier  service;   (iii)  U.S.  Postal  Service  certified  or  registered  mail,  return  receipt requested, postage prepaid.  Service shall be deemed to have been duly given on the date of delivery or on  the date which is seven  (7) days from the date of deposit  in the U.S. Postal  Service  in  the manner  described  above.    Either  party  may  change  the names, addresses  and facsimile  numbers  for receipt  of notice  by complying  with  this Section

17.1.

If to the Company:      DexCom, Inc.
6340 Sequence Drive
San Diego, CA  92121
Attn:  The President

With a copy to            DexCom, Inc.
6340 Sequence Drive
San Diego, CA  92121
Attn:  Legal Department

[*****] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS AND ASTERISKS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED INFORMATION.

(858) 200-0200

[*****] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS AND ASTERISKS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED INFORMATION.

If to the Distributor:
Diabetes Specialty Center, LLC 
3793 South State St. 
Salt Lake City, UT 84115 
Attn: Marc Cohen 

with a copy to:         

Attn:  General Counsel

17.2     Assignment. The Distributor may not assign this Agreement in whole or in part.

		
	17.3 
	Force Majeure.   If either pm1y to this Agreement is delayed or prevented from fulfilling any of its obligations under this Agreement (other than an obligation to pay money) by an event of force majeure, said party shall not be liable under this Agreement for said delay or failure.   "Force  Majeure"  shall  mean any cause  beyond  the reasonable  control of a party including, but not limited  to, acts of God, vandalism, wars, terrorism, civil unrest, blockades,  strikes,  lightning,  fires,  floods, explosions,  hurricanes,  and other  causes not within the control of the party claiming a force majeure situation.   The party claiming an event of force majeure shall promptly notify the other party by providing written notice of the reason for the delay, the anticipated length of time and alternate proposals, if any, which the party wishes to make to alleviate any difficulties or hardships which may be suffered as a result of the delay.  The notification shall be by telephonic communications, confirmed by letter sent in accordance  with Section 17.1. Neither party to this Agreement shall be deemed to be in default by reason of delay or failure due to force majeure.

		
	17.4 
	Waiver.   A waiver by either party of a breach or failure to perform shall not constitute a waiver of any subsequent breach or failure.

		
	17.5 
	Severability.   In the event that any provision of this Agreement  is for any reason held to be invalid or unenforceable or contrary to public policy, such provision shall be treated as severable, leaving valid the remainder of this Agreement.

		
	17.6 
	Counterparts.   This  Agreement  may  be executed  in one or  more counterparts,  each of which  shall constitute  an original  document,  but all of  which  together  shall  constitute only one Agreement.

		
	17.7 
	Applicable Law and Jurisdiction.   This Agreement  shall be governed by the laws of the State of California without regard to such State's conflict of laws principles applicable to contracts  made  and  performed   wholly  with  in  such  State.     The  Distributor hereby irrevocably  agrees  and consents  to  the exclusive  jurisdiction  of  the federal  and state courts located in the State of California  and to accept service by pre-paid registered letter of  any  writ  or  summons  in  any  such  action  notwithstanding   that  Distributor  may otherwise be considered outside the jurisdiction of the California  courts.

[*****] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS AND ASTERISKS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED INFORMATION.

		
	17.8 
	Authorization.  Each of the persons executing this Agreement on behalf of a corporation or  other legal entity  personally  warrants  and  represents  that s/he  has the requisite and necessary approval and authority  to execute this Agreement on behalf of the corporation or other legal entity on whose behalf that person signed.

		
	17.9 
	Entire Agreement.  This Agreement, including amendment(s) if any, together with the Schedules identified herein, constitutes the complete understanding of the parties and supersedes any and all other agreements, ether oral or written, between the parties with respect to the subject matter hereof and no other agreement, statement or promise relating to the subject matter of this Agreement which is not contained herein shall be valid or binding.

17.10   Amendments.  Except for amendments to Schedule 1 regarding pricing and products offered, which Company may amend with 60 days written notice to Distributor, no modification, change or amendment to this Agreement shall be effective unless in writing signed by each of the parties hereto.
IN WITNESS WHEREOF, authorized representatives of the Parties have exectuted this Agreement as of date first set out above.

Signed by:  /s/ Jess Roper_____
       Jess Roper
		
	      
	Chief Financial Officer

Title:

for and on behalf of
DexCom, Inc.

Signed by  /s/ Marc Cohen
Title:
For and on behalf of Diabetes Specialty Center

[*****] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS AND ASTERISKS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED INFORMATION.

SCHEDULE 1

The Products and the Prices

Products - SEVEN PLUS

	
			
	Product
	Description
	Transfer
Price

	STK-7U-030
	SEVEN PLUS Starter Kit
	[****]

	STS-7K-041
	SEVEN Sensors (package of four (4)) ("Sensor 4-pack")
	[****]

	STR-70-030
	SEVEN PLUS Receiver
	[****]

	STT-7U-030
	SEVEN PLUS Transmitter
	[****]

* The Products will be supplied [****]. Freight costs will be included on invoice. Sales tax to be paid by [****].

** [****].

[*****] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS AND ASTERISKS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED INFORMATION.

SCHEDULE2

Ordering Methods

Ordering:  (see note below)
Order merchandise by PRODUCT REORDER NUMBER.

Phone Orders:
Call Customer Service  toll free at 1-877-339-2664 from  6:00 a.m. to 5:00p.m.  Pacific time.  Orders requiring overnight delivery must be placed by 12:00 p.m. Pacific time.

Fax Orders:
Fax to Customer Service,  1--877-633-9266.   Orders requiring overnight delivery must be received by 12:00 p.m. Pacific time.

E-mail Orders:

E-mail to CustomerService@dexcom.com
Attach your purchase order form and utilize the following format when ordering via e­
mail.

Distributor Account Number
Distributor Name
Distributor Bill to and ship to address
Purchase order number
Date Product is required
Ship via [****]
Product Reorder Number
Quantity
Unit Price
Total Price per Line
Contact name, phone, fax and e-mail for confirmation
Notice if confirmation is required.

This e-mail address should be used for ORDERS ONLY.

[*****] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS AND ASTERISKS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED INFORMATION.

Schedule 3
Sales Tracing Report Format

Required Reporting Frequency: Daily

Required Reporting Method or Venue: Web-portal

File Type: csv

De-limiting character: “,” comma with values enclosed by Quotation Marks

Tracing Reports should be in the following format & should not-deviate in order from one report to the next:

	
			
	Field Name
	Type
	Description

	Distributor Branch ID
	Alpha/Numeric
	Distributor ID provided by Distributor (Branch ID)

	DistName
	Alpha/Numeric
	Distributor Name if provided by Distributor

	DistCity
	Alpha/Numeric
	Distributor City if provided by Distributor

	DistState
	Alpha/Numeric
	Distributor State if provided by Distributor

	Referral Source
	Alpha/Numeric
	Designates Dexcom or Distributor referred patient

	Ship-to Party ID
	Alpha/Numeric
	Distributor's Customer ID for this Party

	Ship-to First Name
	Alpha/Numeric
	Customer Name

	Ship-to Last Name
	Alpha/Numeric
	Customer Name

	Ship-to Address1
	Alpha/Numeric
	Facility Address 1

	Ship-to Address2
	Alpha/Numeric
	Facility Address 2

	Ship-to Address3
	Alpha/Numeric
	Facility Address 3

	Ship-to City
	Alpha/Numeric
	Facility City

	Ship-to State
	Alpha/Numeric
	Facility State

	Ship-to ZipCode
	Alpha/Numeric
	Facility Zip code

	Ship-to Phone Number
	Number
	Customer's Phone Number

	Ship-to Date of Birth
	Alpha/Numeric
	Customer's Date of Birth

	Ship-to email
	Alpha/Numeric
	Customer's email address

	Bill-to Party ID
	Alpha/Numeric
	Distributor's Customer ID for this Party

	Bill-to Name
	Alpha/Numeric
	Billing Name

	Bill-to Address1
	Alpha/Numeric
	Facility Address 1

	Bill-to Address2
	Alpha/Numeric
	Facility Address 2

	Bill-to Address3
	Alpha/Numeric
	Facility Address 3

	Bill-to City
	Alpha/Numeric
	Facility City

	Bill-to State
	Alpha/Numeric
	Facility State

	Bill-to ZipCode
	Alpha/Numeric
	Facility Zip code

	Primary Insurance Policy ID #
	Alpha/Numeric
	Customer's Insurance Policy ID #

	Primary Insurance Payor
	Alpha/Numeric
	Customer's Insurance Payer

	PrimaryInsurance Plan
	Alpha/Numeric
	Customer's Insurance Plan

[*****] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS AND ASTERISKS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED INFORMATION.

	
			
	Primary Unique Insurance #
	Alpha/Numeric
	Distributor's Unique Identifier for this specific plan at the lowest level

	Primary Insurance Phone #
	Alpha/Numeric
	Customer's Insurance Payer's Phone #

	 
	 
	 

	 
	 
	 

	Secondary Insurance Policy ID #
	Alpha/Numeric
	Customer's Insurance Policy ID #

	Secondary Insurance Payor
	Alpha/Numeric
	Customer's Insurance Payer

	Secondary Insurance Plan
	Alpha/Numeric
	Customer's Insurance Plan

	Secondary Unique Insurance #
	Alpha/Numeric
	Distributor's Unique Identifier for this specific plan at the lowest level

	Secondary Insurance Phone #
	Alpha/Numeric
	Customer's Insurance Payer's Phone #

	Secondary Insurance Co-Pay Amount
	Currency
	Customer's portion of  financial responsibilty

	Secondary Insurance Allowable Amount
	Currency
	Financial Amount Insurance Company will Cover

	Persription Expiration Date
	Date
	Persription Expiration Date (MM/DD/YYYY)

	Perscribing Physician's NPI #
	Alpha/Numeric
	Physician's National Provider Identifier (NPI) #

	Perscribing Physician's Last Name
	Alpha
	Perscribers Last Name

	Perscribing Physician's First Name
	Alpha
	Perscribers First Name

	Perscribing Physician's City
	Alpha/Numeric
	Perscribing Physician's City

	Perscribing Physician's State
	Alpha
	Perscribing Physician's State

	Perscribing Physician's Zip
	Number
	Perscribing Physician's Zip

	Contract#
	Alpha/Numeric
	Distributor's Contract Number

	Transaction Type Description
	Alpha/Numeric
	Product Transaction Type: What type of sale is this? Standard Sale, Return, Inventory Adjustment, Transfer between branches.

	Return Good Authorization (RGA) Number
	Alpha/Numeric
	Quality Number procured from Dexcom, if product is to be returned to Dexcom

	Invoice/Transaction Number (Debit or Credit)
	Alpha/Numeric
	Distributor's Invoice/Transaction Number (Debit or Credit)

	InvoiceDate
	Date
	Date of Distributor's Invoice (MM/DD/YYYY)

	ProductID
	Alpha/Numeric
	Manufacturer Product ID (SKU)

	ProductDescription
	Alpha/Numeric
	Product Description reported by Distributor

	Product Serial Number
	Alpha/Numeric
	Product's Serial Number (only applicable for STKs)

	Product Lot Number
	Alpha/Numeric
	Product's Lot Number

	Quantity
	Number
	Quantity Sold

	UOM
	Alpha/Numeric
	Product Unit of Measure (i.e. kit, 4-pack box, sensor, crate, skid)

	UnitCost
	Currency
	Distributor's Contract Cost (If provided) - Unit Cost preferred to Total Cost

	UnitRebate
	Currency
	Distributor's Rebate (if claimed) - Unit Rebate preferred to Total Rebate

[*****] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS AND ASTERISKS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED INFORMATION.

Schedule 4
Forecast, Ordering and Acceptance Requirements

I.    Forecast.   Once Distributor's orders from its existing installed base exceeds more than 50 starter kits per month, Distributor shall deliver to Company its forecast (the "Forecast") of the expected requirements for Products in the Territory for the following twelve (12) month pe1iod. Thereafter, Distributor shall update such Forecast on a quarterly basis and provide it to Company at least five days prior to the first of each  calendar
quarter.

II.     Orders, Shipping.  Orders will be initiated by a written order, electronic equivalent or facsimile issued to DexCom (the "Order"). Each Order shall include information as set forth in Schedule 2. The first Order provided by Distributor shall cover the first binding commitment period.  Each subsequent Order shall cover the new binding commitment from the Forecast.  Products to be delivered per dates indicated on firm Orders shall be subject to a minimum of [****] lead time afforded to the Company.  An Order shall be deemed to have been placed as of the date of receipt of the Order by Company.  The Company shall promptly acknowledge receipt of each Order in writing, via fax or email and shall without undue delay confirm such order, unless such order is for a quantity in excess of the
Forecast, in which case the Company shall confirm it if it is able to meet such order using commercially reasonable efforts. If the aggregate of the quantities ordered are less than the quantity committed in the Forecast, Distributor shall be deemed to have submitted additional Orders for the balance, to be delivered in the following calendar quarter. If Distributor requests Company to supply quantities in any calendar quarter in excess of the maximum quantity committed in the Forecast, Company shall endeavor reasonably within the constraints of its production schedules and other commitments to meet all or part of
such requests, but Company shall have no obligation to supply quantities in excess of the maximum qum1tity committed under the Forecast.  Where necessary, Company will advise Distributor of necessary revisions to delivery dates and quantities for the portion of
Order(s) in excess. For any Order (or portion thereof) having a shorter lead time than the agreed-to lead time requirements set forth herein, or in excess of the Forecast, Company shall use commercially reasonable efforts to accommodate such shorter lead time or fill such excess. All freight, insurance and other shipping expenses, as well as any special packing expenses, will be paid by Distributor.

III.     Acceptance.  If and when Distributor receives any shipments, then within [****]  following a receipt of a shipment, Distributor shall perform a visual inspection (in accordance with Distributor's standard procedures) of the Products  received and shall inform Company in writing of any non-conformity  of the supplied Products to the specifications as shown in such inspection or other defect in the Products.  In the absence of written notice to Company of a specified non-conformity  within [****] days of the end of [****]  period, the Products shall be deemed to be accepted by Distributor. If any latent defect in the Products is subsequently discovered that is not the result of Distributor's or its agents' handling, modification, or 

[*****] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS AND ASTERISKS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED INFORMATION.

storage of the Products since delivery to the carrier by Company, Distributor shall promptly so inform Company together with all available details and information regarding the situation, including all records of Distributor's  or its agents' handling, modification, and storage of the Products since delivery to the carrier by Company. In case of a justifiable claim of non-conformity, Company shall either (at Company's option) replace the defective portion of the Products at no additional cost to Distributor or cancel the order and refund any portion of the price that may to that time have been paid to Company under this Agreement for the sale in question. If Distributor rejects any Products and Company does not agree that Distributor is justified in doing so, the parties will attempt to resolve the situation in good faith, and if necessary, an independent laboratory acceptable to both parties shall utilize agreed upon test methods to test the products in dispute and to audit Distributor's and its agents' handling and storage of the products since delivery to the carrier by Company.  The costs of such independent laboratory shall be borne by the parties equally; provided, however, that the party that is determined to have been incorrect in the dispute shall be responsible for all such costs and shall reimburse the correct party for its share of the costs incurred. The independent laboratory's findings shall be in writing and shall be binding on both parties.

[*****] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS AND ASTERISKS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED INFORMATION.

Amendment Number One to Non-Exclusive Distribution Agreement

This Amendment Number One to the Non-Exclusive Distribution Agreement (“Amendment Number One”) is made as of this 30 day of September, 2010, by and between DexCom, Inc., a Delaware corporation, with a principal place of business at 6340 Sequence Drive, San Diego, California 92121 (the "Company") and Diabetes Specialty Center LLC, a Utah corporation with offices at 3793 South State St., Salt Lake City, UT  84115 (the “Distributor”). 

WITNESSETH

WHEREAS, Company and Distributor previously entered into a Non-Exclusive Distribution Agreement, effective October 12, 2009 (the “Agreement”). 

WHEREAS, Company and Distributor wish to amend the Agreement as set forth herein in accordance with Section 2.2 and 17.10 of the Agreement. 

THEREFORE, Company and Distributor agree as follows:  

1.    Schedule 1.  Schedule 1 shall be amended to read as follows:

SCHEDULE 1
The Products and the Prices

Pricing set forth below shall be effective on October 1, 2010.

SEVEN PLUS

[*****] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS AND ASTERISKS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED INFORMATION.

 
	
			
	Product SKU
	Product Description
	Transfer Price*

	STK-7U-030
	SEVEN PLUS Starter Kit*
	[****]

	STS-7K-041
	SEVEN Sensors (package of four (4))*
	[****]

	STR-7U-030
	SEVEN PLUS Replacement Receiver*
	[****]

	STT-7U-030
	SEVEN PLUS Replacement Transmitter*
	[****]

*  The Products will be supplied [****] and sales tax to be paid by [****].
** [****]

2.   Section 4.  A new section 4.1.31 shall be added as follows:

4.1.31.    not to sell any Products where the shelf-life on the Product is less than the time of reasonable consumption by the Customer, and in no instance to ship Product with a shelf-life of less than [****]. 

3.    Section 4.  A new section 4.1.32 shall be added as follows:  

4.1.32.  to adhere to the requirements set forth in the Quality Agreement, Schedule 5;

		
	4.
	Section 4.  A new section 4.1.33 shall be added as follows:  

4.1.33.  to ship Products to Customer within 3 business days of receiving prior authorization approval from the Customer’s insurance company, or in the alternative, 

[*****] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS AND ASTERISKS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED INFORMATION.

upon notice of a denial of a prior authorization request, to inform the Company within 24 hours of such denial;

      5.  Section 4:   A new section 4.1.34 shall be added as follows:  

4.1.34.  to provide, within seven days of the end of each calendar month, a report detailing Distributor’s month-end inventory balance of Products (which report Company shall retain the right to audit on a periodic basis with advance notice to Distributor). 

6.  Section 5.  A new section 5.1.4 shall be added as follows:

5.1.4.     to stock sensors with Distributor based on purchase orders submitted by Distributor.

       
7.  Schedule 5.  A new Schedule 5 shall be added as follows:

Quality Agreement
		
	1.0
	SCOPE

		
	1.1
	This Quality Agreement (the “Quality Agreement”) is incorporated within the Distribution Agreement that was effective October 12, 2009, between Distributor and Company pertaining to the distribution and sale of Products (the “Agreement”).  Capitalized terms not otherwise defined herein shall have the meaning assigned to them in the Agreement.  To the extent the terms of the Quality Agreement and the Agreement conflict, the terms set forth in the Quality Agreement shall superseded the Agreement.

		
	1.2
	This Quality Agreement shall be effective on the Effective Date and shall remain in effect until the Agreement expires, is terminated or the Quality Agreement is modified.

		
	2.0
	PROCESS CONTROLS 

		
	2.1
	Distributor shall be responsible for supplier appropriate process control activities relative to the Products, including but not limited to, assurance of receipt, identification, traceability, storage, handling, inventory control and facility contamination control.

		
	2.2
	Company shall provide evidence that packaging containers maintain the integrity, quality, function, and sterility of the product for the entire shelf life, and not produce toxic residues during storage.  Packaging must prevent or indicate the occurrence of tampering.

[*****] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS AND ASTERISKS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED INFORMATION.

		
	3.0
	TRAINING AND DOCUMENT CHANGE CONTROL 

		
	3.1
	Distributor must train its employees to perform their job function and to this Quality Agreement as required.

		
	4.0
	QUALIFICATION

		
	4.1
	Distributor shall be responsible for managing qualified processes and systems as required of suppliers (e.g. computer system) by law.

		
	5.0
	DISTRIBUTION AND HANDLING

		
	5.1
	Products shipped by the Distributor must be shipped using standard procedures for the handling, storage, packaging, preservation, and delivery of the Products.  

		
	5.2
	Distributor shall deliver Products to its customers using standard procedures for handling, storage, packing, preservation, and delivery of the Products.

		
	6.0
	LOT TRACEABILITY 

		
	6.1
	Distributor shall establish and maintain appropriate procedures for identifying the Products by suitable means from receipt and during all stages of delivery.  

	
			
	Product
	Description
	Lot traceability Tracking Requirement

	STK-7U-030
	SEVEN PLUS System Kit
	Lot Number identified on the box

	STS-7K-041
	SEVEN Sensors (package of four (4))
	Lot Number identified on the box

	STR-7U-030
	SEVEN PLUS Replacement Receiver
	Lot Number identified on the box

	STT-7U-030
	SEVEN PLUS Replacement Transmitter
	Lot Number identified on the box

		
	7.0
	PACKAGING AND LABELING

		
	7.1
	Company shall provide packaging and labeling specifications that call out clear labeling requirements. 

		
	7.2
	Company shall ensure that the labels, inserts and accompanying documentation satisfy the requirements of the applicable regulations.

[*****] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS AND ASTERISKS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED INFORMATION.

		
	8.0
	COMPLAINT HANDLING AND REPORTING

		
	8.1
	Distributor shall be responsible for the establishment and maintenance of a system for handling complaints pertaining to the process of distributing Products under the Agreement pursuant to current Distributor policy.  This system shall include receipt, review, corrective/preventative action and maintenance of files.  Distributor will not knowingly perform any Device Complaint handling, as defined below.  

		
	8.2
	Company shall be responsible for the establishment and maintenance of a system for handling Device Complaints pertaining to Products distributed under the Agreement.  A “Device Complaint” includes complaints that pertain to Product functionality, trouble shooting, or adverse events.  This system shall include receipt, review, investigation, corrective/preventative action and maintenance of files.

		
	8.3
	Company shall notify Distributor in writing of legal and regulatory matters relating to the Products, including:

		
	8.3.1
	Any regulatory actions by governmental authorities (e.g., inspection citations, warning letters, or other non-conformance notices).

		
	8.3.2
	Regulatory enforcement actions such as injunctions or seizures.

		
	8.3.3
	FDA registration activity (e.g., non-conformance notices, hold points).

		
	8.3.4
	Complaints received from Customers within the Territory that have not been processed through the Company’s complaint handling system.

		
	8.3.5
	Adverse incidents relating to Customers within the Territory (e.g., MDR’s.).

		
	8.4
	Distributor shall notify Company in writing of the following:

		
	8.4.1
	Any serious regulatory action relating to the Products that Distributor may become aware of.

		
	8.4.2
	Escalated Complaints regarding Products or Instruments. Distributor shall code, trend and report monthly Escalated Complaint data pertaining to Products, at Distributor’s request.  

		
	8.4.3
	Distributor shall forward all complaints pertaining to Products and Instruments to Company no later than 10 working days following Distributor’s initial receipt of the complaint.

		
	9.0
	FIELD ACTIONS

		
	9.1
	The Company will be responsible for the initiation and cost of any recalls or other field actions related to the Products.

		
	9.2
	Both parties will comply with recalls or general corrective actions, provided such recalls or general corrective actions do not, in the opinion of Company violate or cause Company to violate the laws of any jurisdiction affected by the recalls or corrective action.

		
	9.3
	If Distributor and Company do not agree on a course of action, Company may initiate field actions related to the Products, but may not use field action to cause Distributor to lose Customers. 

[*****] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS AND ASTERISKS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED INFORMATION.

		
	10.0
	AUDITS

		
	10.1
	Company shall have the right to conduct audits of Distributor’s facilities and operations during normal business hours and upon reasonable notice to Distributor in order to assess compliance with all applicable regulations, procedures and this Quality Agreement.  Any such audits will be conducted by a national “big four” independent accounting firm (or other independent accounting firm whose audit department is a separate stand alone function of its business and which possesses liability insurance with coverage of at least [****]), subject to such firm’s execution of a confidentiality agreement in form reasonably acceptable to Distributor. Company shall be permitted to conduct one audit per calendar year.

		
	11.0
	RECORD RETENTION

		
	11.1
	Both parties shall retain all medical records as required by law.  

		
	12.0
	REGULATORY AND REGISTRATION ADMINISTRATION

		
	12.1
	Company, at its expense, is responsible for registration responsibilities, and for agreed upon registration costs of Products in the Territory.  Company shall provide sufficient data and information to support such registrations.

		
	13.0
	ADDITIONAL DISTRIBUTOR REQUIREMENTS

		
	13.1
	Records should be accurate, indelible and legible. Entries must be dated and the person performing a documented task must be identified. Records must provide a complete history of the work performed. 

[*****] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS AND ASTERISKS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED INFORMATION.

8.   All other terms and conditions of the Agreement shall remain in full force and effect.

IN WITNESS WHEREOF, authorized representatives of the parties have executed this Amendment Number One as of date first set out above.

Signed by:    /s/ Jess Roper            
Jess Roper
Title:      V.P. and Chief Financial Officer

for and on behalf of
DexCom, Inc.

Signed by:  /s/ Marc Cohen                
Name: 
Title:          

for and on behalf of Diabetes Specialty Center

[*****] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS AND ASTERISKS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED INFORMATION.

Diabetes Specialty Center LLC

Amendment Number Two to Non-Exclusive Distribution Agreement

This Amendment Number Two to the Non-Exclusive Distribution Agreement (“Amendment Number Two”) is made as of this 11th day of October, 2011, by and between DexCom, Inc., a Delaware corporation, with a principal place of business at 6340 Sequence Drive, San Diego, California 92121 (the "Company") and Diabetes Specialty Center LLC, a Utah corporation with offices at 3793 South State St., Salt Lake City, UT  84115 (the “Distributor”). 

WITNESSETH

WHEREAS, Company and Distributor previously entered into a Non-Exclusive Distribution Agreement, effective October 12, 2009, as amended by Amendment Number One to the Non-Exclusive Distribution Agreement, effective September 30, 2010 (collectively, the “Agreement”). 

WHEREAS, Company and Distributor wish to amend the Agreement as set forth herein in accordance with 17.10 of the Agreement. 

THEREFORE, Company and Distributor agree as follows:  

		
	1.
	Section 12.1 of the Agreement shall be amended and restated to read as follows:

12.1    Subject to the following provisions, this Agreement was effective on October 12, 2009, and shall renew automatically for successive one year terms on each subsequent October 12; provided that either party may terminate this Agreement upon [****] advance written notice to the other party.  

2.   All other terms and conditions of the Agreement shall remain in full force and effect.

[*****] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS AND ASTERISKS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED INFORMATION.

[REMAINDER OF PAGE LEFT INTENTIONALLY BLANK]

[*****] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS AND ASTERISKS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED INFORMATION.

IN WITNESS WHEREOF, authorized representatives of the parties have executed this Amendment Number Two as of date first set out above.

Signed by:    /s/ Jess Roper            
Jess Roper
Title:      V.P. and Chief Financial Officer

for and on behalf of
DexCom, Inc.

Signed by:            /s/ Marc Cohen    
Name: 
Title:          

for and on behalf of 
Diabetes Specialty Center LLC

[*****] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS AND ASTERISKS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED INFORMATION.

Amendment Number Three to Non-Exclusive Distribution Agreement

This Amendment Number Three to the Non-Exclusive Distribution Agreement (“Amendment Number Three”) is made as of this 14 day of November, 2012, by and between DexCom, Inc., a Delaware corporation, with a principal place of business at 6340 Sequence Drive, San Diego, California 92121 (the "Company") and Byram Healthcare and all subsidiaries, a Utah corporation with a principal office at 3793 S. State Street, Salt Lake City, Utah 84115 (the “Distributor”). 

WITNESSETH

WHEREAS, Company and Distributor previously entered into a Non-Exclusive Distribution Agreement, effective October 12, 2009, as amended on September 30, 2010 and October 11, 2011, and pursuant to the Dexcom consent to the assignment of the Non-Exclusive Distribution Agreement to Byram Healthcare dated May 2, 2012 (the “Agreement”). 

WHEREAS, Company and Distributor wish to amend the Agreement as set forth herein in accordance with Section 2.2 and 17.10 of the Agreement. 

THEREFORE, Company and Distributor agree as follows:  

 1.  SECTION 4.  Section 4.1.31 is amended and restated in its entirety as follows:

4.1.31  not to stock more than one month of Receiver, Transmitter and Sensor inventory; provided however that Company acknowledges that, from time to time, Distributor may stock an amount of Receiver, Transmitter and Sensor inventory equal to more than one month based on demand fluctuations.  Distributor also agrees not to sell any Sensors where the shelf-life on the Sensors is less than the time of reasonable 

[*****] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS AND ASTERISKS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED INFORMATION.

consumption by the Customer, and in no instance to ship Sensors with a shelf-like of less than [****].

 2.  SECTION 4.  Section 4.1.34 is amended and restated in its entirety as follows:

4.1.34  to provide, within [****] of the end of each calendar month, a report detailing Distributor’s month-end inventory balance of Products (which report Company shall retain the right to audit on a periodic basis with advance notice to Distributor).

 3.  SECTION 4.  A new section 4.1.35 shall be added as follows: 

4.1.35  to maintain a valid and current prescription on file for ongoing product orders.

 4.  SECTION 4.  A new section 4.1.36 shall be added as follows:

4.1.36  to ship the Products on or before the date indicated on the Product packaging, if applicable, which appears in the following format: SB- YYYY-MM-DD (the “Ship-By Date”).  If the Product packaging does not contain a Ship-By Date, then Distributor shall ship the Product at least two (2) months prior to the expiration date listed on the Product packaging (the “Expiration Date”) or with at least [****] of shelf life left ("Shelf Life Date", and together with the Ship-By Date and Expiration Date, the "Required Ship Date).  If Distributor fails to ship Products by the applicable Required Ship Date, then Distributor shall be obligated to pay or cure any product warranty claims or defective product claims at its own cost and expense, and/or reimburse the Company for any related costs or expenses the Company incurs.

5.    SCHEDULE 1.  Schedule 1 is amended and restated in its entirety as follows:  

[*****] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS AND ASTERISKS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED INFORMATION.

    
Products – 

Dexcom SEVEN PLUS
 
	
			
	Product
	Description
	Transfer Price*

	STS-7K-041
	SEVEN Sensors (package of four (4))
	[****]

Dexcom G4 Platinum
 
	
			
	Product
	Description
	Transfer Price*

	STS-GL-041
	Dexcom G4 Platinum Sensor Kit (package of four (4))
	[****]

	STK-GL-001
	Dexcom G4 Platinum Receiver Kit – BLK
	[****]

	STK-GL-PNK
	Dexcom G4 Platinum Receiver Kit – PNK
	[****]

	STK-GL-BLU
	Dexcom G4 Platinum Receiver Kit – BLU
	[****]

	STS-GL-003
	Dexcom G4 Transmitter Kit
	[****]

     

*  The Products will be supplied [****] and sales taxes to be paid by [****].
** [****]

		
	6.
	SCHEDULE 3.  Schedule 3 is amended and restated in its entirety as follows:  

[*****] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS AND ASTERISKS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED INFORMATION.

SCHEDULE 3

Sales Tracing Report Format

		
	Required Reporting Frequency:  
	Daily

Format: .csv (comma-delimited file)
		
	Delivery method:  
	Dexcom controlled secure file transfer protocol site specific to the distributor

Sales tracings will include the following fields:

[*****] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS AND ASTERISKS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED INFORMATION.

	
			
	 
	 
	 

	Field
	Format
	Comments

	Customer ID Number
	Text
	A unique identifying number for each customer

	Customer First Name
	Text
	 

	Customer Last Name
	Text
	 

	Customer Address
	Text
	For ZIP Code use 5-character; text so leading zeros are included; no Zip + 4 numbers

	Customer DOB
	Text
	MM/DD/YYYY

	Physician First Name
	Text
	 

	Physician Last Name
	Text
	 

	Physician ZIP Code
	Text
	5-character; text so leading zeros are included; no Zip + 4 numbers

	Physician NPI
	Text
	 

	Insurance Name
	Text
	 

	Dexcom Item Number
	Text
	 

	Item Quantity
	Text
	Unit quantity - e.g. 1 box of sensors is '1', and not the number of individual sensors included

	Date of Shipment
	Text
	MM/DD/YYYY

	Hardware serial number
	Text
	Where distributor stocks and ships hardware

	Shipper
	Text
	Dexcom or Distributor, where distributor provides tracings including shipments from both locations

	 
	 
	 

[END OF SCHEDULE 3]

[*****] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS AND ASTERISKS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED INFORMATION.

       
		
	7.
	SCHEDULE 5.  Schedule 5 is amended and restated in its entirety as follows:  

Quality Agreement
		
	1.0
	SCOPE

		
	1.1
	This Quality Agreement (the “Quality Agreement”) is incorporated within the Distribution Agreement dated October 12, 2009, as amended on September 30, 2010 and October 11, 2011 between Distributor and Company pertaining to the distribution and sale of Products.  Capitalized terms not otherwise defined herein shall have the meaning assigned to them in the Agreement.

		
	1.2
	This Quality Agreement shall be effective on the Effective Date and shall remain in effect until the Agreement expires, is terminated or the Quality Agreement is modified.

    
		
	2.0
	DEFINITIONS / ACRONYMS

		
	2.1
	“Applicable Documents”:  Documents used to develop a specific document (i.e. standards, regulations) and documents referenced in the text of the specific document.

		
	2.2
	"Government Agency" means any body which has the authority to act on behalf of the government of the Union or State to ensure that the requirements of all laws applicable to the Products and Distributor are carried out and adhered to in the State.

		
	2.3
	"Customer Complaint" means any written, electronic or oral communication that alleges deficiencies related to the identity, quality, durability, reliability, safety or performance of a medical device that has been placed on the market.

		
	2.4
	“CGM”: Continuous Glucose Monitoring.

		
	2.5
	“Correction” means repair, modification, adjustment, relabeling, destruction, or inspection (including patient monitoring) of a product without its physical removal to some other location.

		
	2.6
	“Document” means any information, either written or stored electronically, including specifications, procedures, standards, methods, instructions, plans, files, forms, notes, reviews, analyses, and reports.

		
	2.7
	“Government Agency” means a federal (e.g. FDA) or state (Health and Human Services Food and Drug Branch) organization that has the power to provide services for conformity assessment on the conditions set out in the Federal Food, Drug, and Cosmetic Act (FD&C Act) and United States Code (U.S.C) as part for the sale of medical device products. This normally means assessing the manufacturers conformity to the essential requirements listed in each directive. 

		
	2.8
	 “Lot” or “Batch” means one or more components or finished devices that consist of a single type, model, class, size, composition, or software version that are manufactured 

[*****] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS AND ASTERISKS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED INFORMATION.

under essentially the same conditions and that are intended to have uniform characteristics and quality within specified limits.
		
	2.9
	“Label” means a display of written, printed, or graphic matter upon the immediate container of any article.  Any word, statement, or other information appearing on the immediate container must also appear “on the outside container or wrapper, if any there be, of the retain package of such article, or is easily legible through the outside container of wrapper.”

		
	2.10
	“Labeling” means any  Labels and other written, printed, or graphic matter (1) upon any article or any of its containers or wrappers, or (2) displaying such article” at any time while a device is held for sale after shipment or delivery for shipment in interstate commerce.

		
	2.11
	 “Quality Records” means Documents containing recorded information, regardless of the medium or characteristic, which demonstrate the effectiveness of the quality management system and that provide evidence that products meet regulatory requirements and comply with specified product requirements.

		
	2.12
	“Removal” means the physical removal of a device from its point of use to some other location for repair, modification, adjustment, relabeling, destruction, or inspection.

		
	2.13
	“Stock Recovery” means the correction or removal of a device that has not been marketed or that has not left the direct control of the manufacturer, i.e., the device is located on the premises owned, or under the control of, the manufacturer, and no portion of the lot, model, code, or other relevant unit involved in the corrective or removal action has been released for sale or use.

		
	2.14
	"Recall" means when there is a risk of death or serious deterioration to the state of health, the return of a medical device to the supplier, its modification by the supplier at the site of installation, its exchange or its destruction, in accordance with the instructions contained in the advisory notice.

		
	2.15
	"Medical Device Reporting System" is a system of incident reporting to the Federal Food and Drug Administration (FDA), for all medical devices which are approved for inter-state commerce, where such incidents lead to corrective action relevant to medical devices.  Medical Device Reporting Systems maintained by the Distributor shall comply with all applicable laws, the rules and regulations promulgated by the Federal or any State. This system is intended to allow data to be correlated between the FDA and manufactures to improve the protection of health and safety of patients, users and others by reducing the likelihood of the same type of adverse incident being repeated in different places at different times. 

		
	3.0
	PROCESS CONTROLS

		
	3.1
	Both parties shall be responsible for all process control activities relative to the Products, including but not limited to, assurance of receipt, identification, traceability, storage, handling, inventory control, contamination control, complaint handling and trending and process validations, as required by Title 21 of United States Code of Federal Regulations, and other applicable regulations, and governmental laws.

		
	3.2
	Both parties shall maintain appropriate documented procedures.

[*****] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS AND ASTERISKS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED INFORMATION.

		
	3.3
	Company shall provide evidence that packaging containers maintain the integrity, quality, function, and sterility of the product for the entire shelf life, and not produce toxic residues during storage.  Packaging must prevent or indicate the occurrence of tampering.

		
	4.0
	TRAINING AND DOCUMENT CHANGE CONTROL

		
	4.1
	Distributor shall be responsible for managing an effective employee training program and document change control system relative to the receipt, identification, traceability, storage, handling, inventory control, contamination control and complaint handling and trending at the location of Distributor and its third party suppliers.

		
	4.2
	Distributor must train its employees to perform their job function and to this Quality Agreement as required.

		
	5.0
	VALIDATION

		
	5.1
	Distributor shall be responsible for managing qualified processes and systems as required of suppliers (e.g. computer system) by law.

		
	5.2
	Both parties shall be responsible for managing an effective product and process validation system relative to the distribution of the Products at the location of the Distributor and its third party suppliers.

		
	5.3
	Both parties shall develop and implement validation or qualification protocols for significant processes, equipment, and computer systems.

		
	5.4
	Company shall be responsible for managing an effective product and process validation system relative to the manufacture of the Products at the location of the Company and its third party suppliers.

		
	6.0
	DISTRIBUTION AND HANDLING

		
	6.1
	Products shipped by the Distributor must be shipped using documented procedures for the handling, storage, packaging, preservation, and delivery of the Products.  

		
	6.2
	Distributor shall deliver Products to its customers using documented procedures for handling, storage, packing, preservation, and delivery of the Products.

		
	6.3
	Disposables must have at least three months of expiration dating left, unless specific variance by lot number has been agreed to by both parties, before being shipped to any end-user customer.  

		
	6.4
	The Distributor will not modify any product packaging that it receives from the Company.  Shipping containers shall be validated to ensure that the safety and integrity of the Product is maintained during transit, including shipping methods that conform with the Product’s acceptable temperature and humidity ranges.

		
	6.5
	Distributor must maintain storage & handling as follows:

Seven Plus Product

[*****] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS AND ASTERISKS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED INFORMATION.

	
			
	Product Name
	Storage Temperature
	Humidity

	Sensor
	2-25°C (36-77°F)
	N/A

	Transmitter
	0-45°C (32-113°F)
	Max 95% Relative

	Receiver
	0-45°C (32-113°F)
	10-85% Relative

G4 Platinum Product
	
			
	Product Name
	Storage Temperature
	Humidity

	Sensor
	2-25°C (36-77°F)
	15-85% Relative

	Transmitter
	0-45°C (32-113°F)
	10-95% Relative

	Receiver
	0-45°C (32-113°F)
	10-95% Relative

		
	7.0
	LOT TRACEABILITY

		
	7.1
	Distributor shall establish and maintain procedures for identifying the Products by suitable means from receipt and during all stages of production and delivery.  This shall include procedures to provide full lot traceability for each unit, lot, or batch of finished Products during all stages of production and delivery to the Distributor.  

		
	7.2
	Distributor shall establish and maintain procedures to provide traceability to the first consignee.

		
	7.3
	Distributor shall establish and maintain procedures to provide traceability to the end user.

		
	7.4
	Both parties shall use reasonable efforts to assist the other in maintaining respective lot traceability.

		
	7.5
	Both parties are required to track the following information detailed in the table to the end user. 

		
	8.0
	Seven Plus Product

	
			
	Product
	Description
	Lot traceability Tracking Requirement

	STK-7U-030
	SEVEN PLUS System Kit
	Lot Number identified on the box

	STS-7K-041
	SEVEN Sensors (package of one (1) or four (4))
	Lot Number identified on the box

	STR-7U- 030
	SEVEN PLUS Replacement Receiver
	Lot Number identified on the box

	STT-7U- 030
	SEVEN PLUS Replacement Transmitter
	Lot Number identified on the box

[*****] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS AND ASTERISKS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED INFORMATION.

		
	9.0
	G4 Platinum Product

	
			
	Product
	Description
	Lot traceability Tracking Requirement

	STK-GL-001
	G4 Platinum Receiver Kit – BLK
	Lot Number identified on the box

	STK-GL-PNK
	G4 Platinum Receiver Kit – PNK
	Lot Number identified on the box

	STK-GL-BLU
	G4 Platinum Receiver Kit – BLU
	Lot Number identified on the box

	STT-GL-003
	G4 Transmitter Kit
	Lot Number identified on the box

	STR-GL-001
	G4 Platinum Replacement Receiver Kit – BLK
	Lot Number identified on the box

	STR-GL-PNK
	G4 Platinum Replacement Receiver Kit – PNK
	Lot Number identified on the box

	STR-GL-BLU
	G4 Platinum Replacement Receiver Kit – BLU
	Lot Number identified on the box

	STS-GL-011
	G4 Platinum Sensors Kit (package of one (1))
	Lot Number identified on the box

	STS-GL-041
	G4 Platinum Sensors Kit (package of four (4))
	Lot Number identified on the box

		
	10.0
	PACKAGING AND LABELING

		
	10.1
	Company shall provide packaging and labeling specifications that call out clear labeling requirements. 

		
	10.2
	Company shall ensure that the labels, inserts and accompanying documentation satisfy the requirements of the applicable regulations.

		
	10.3
	Distributor shall not modify the labels, primary or secondary packaging, inserts or accompanying documentation without the written approval of the Company.

		
	11.0
	 FINISHED PRODUCT NON-CONFORMANCES

		
	11.1
	Any nonconforming finished product requires written approval from Company’s Quality Assurance before shipment to any Customer by Distributor. 

[*****] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS AND ASTERISKS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED INFORMATION.

		
	12.0
	COMPLAINT HANDLING AND REPORTING

		
	12.1
	Distributor shall be responsible for the establishment and maintenance of a system for handling all Tier I Complaints pertaining to Products distributed under the Agreement.  "Complaint" means any written, electronic, telephone call and/or oral communication that alleges deficiencies related to the identity, quality, durability, reliability, safety, effectiveness, or performance of a device after it is released to distribution.  A complaint is any indication of the failure of a device to meet customer or user expectations for quality or to meet performance specifications.  A “Tier I Complaint” includes complaints that pertain to the purchase, payment, billing, delivery, packaging and customer service.  This system shall include receipt, review, corrective/preventative action and maintenance of files.  Distributor will not perform any Tier II Complaint Handling, as defined below.  

		
	12.2
	Company shall be responsible for the establishment and maintenance of a system for handling Tier II Complaints pertaining to Products distributed under the Agreement.  A “Tier II Complaint” includes complaints that pertain to product functionality, trouble shooting, or adverse events.  This system shall include receipt, review, investigation, corrective/preventative action and maintenance of files.  It shall also include adverse event reporting to the appropriate governmental authorities as required by regulations in the applicable jurisdictions.

		
	12.3
	Company shall notify Distributor in writing of legal and regulatory matters relating to the Products, including:

		
	12.3.1
	Any regulatory actions by governmental authorities (e.g., inspection citations, warning letters, or other non-conformance notices).

		
	12.3.2
	Regulatory enforcement actions such as injunctions or seizures.

		
	12.3.3
	FDA registration activity (e.g., non-conformance notices, hold points).

		
	12.3.4
	Complaints received from Customers within the Territory that have not been processed through the Company’s complaint handling system.

		
	12.3.5
	Adverse incidents relating to customers within the Territory (e.g., MDR’s.).

		
	12.4
	Distributor shall notify Company in writing of the following:

		
	12.4.1
	Any serious regulatory action relating to the Products.

		
	12.4.2
	Tier I Complaints regarding Products or Instruments. Distributor shall code, trend and report monthly all phone call inquiries and Tier I Complaint data pertaining to Products.  

		
	12.4.3
	If an adverse incident is received that may be subject to FDA’s Medical Device Reporting regulation that pertain to Products and Instruments, then Distributor shall notify Company  no later than 24 hours following Distributor’s initial receipt of the adverse event.

		
	12.4.4
	  Distributor shall forward all complaints pertaining to Products and Instruments to Company no later than 5 working days following Distributor’s initial receipt of the complaint.

		
	13.0
	FIELD ACTIONS

		
	13.1
	The Company will be responsible for the initiation of any recalls or other field actions related to the Products.

[*****] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS AND ASTERISKS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED INFORMATION.

		
	13.2
	Both parties will comply with recalls or general corrective actions, provided such recalls or general corrective actions do not, in the opinion of Company violate or cause Company to violate the laws of any jurisdiction affected by the recalls or corrective action.

		
	13.3
	If Distributor and Company do not agree on a course of action, Company may initiate field actions related to the Products, but may not use field action to cause Distributor to lose Customers. 

		
	14.0
	AUDITS

		
	14.1
	  Company shall have the right to conduct audits of Distributor’s facilities and operations during normal business hours at its own expense and upon thirty (30) days notice to Distributor in order to assess compliance with all applicable regulations, procedures and this Quality Agreement.  Any such audits will be conducted by a national “big four” independent accounting firm (or other independent accounting firm whose audit department is a separate stand alone function of its business and which possesses liability insurance with coverage of at least [****]), subject to such firm’s execution of a confidentiality agreement in form reasonably acceptable to Distributor. Company shall be permitted to conduct one audit per calendar year or more frequently in the instance there exists a material difference between the inventory records of Distributor and Company.

		
	15.0
	RECORD RETENTION

		
	15.1
	Both parties shall retain all sales and medical records as required by law.  

		
	15.2
	Prior to any record destruction pertaining to Company Products and Instruments, the Distributor will notify the Company in writing.  If the record destruction is not approved the Company will assume responsibility of the records.

		
	16.0
	REGULATORY AND REGISTRATION ADMINISTRATION

		
	16.1
	Distributor, at its expense, is responsible for registration responsibilities, and for agreed upon domestic registration costs in accordance with Federal and State regulations.  Distributor shall provide sufficient data and information to support domestic registrations.

		
	16.2
	Company, at its expense, is responsible for registration responsibilities, and for agreed upon registration costs of Products in the Territory.  Company shall provide sufficient data and information to support such registrations.

		
	17.0
	QUALITY SYSTEM COMPLIANCE

		
	17.1
	Distributor shall establish and maintain a quality system in compliance with Title 21, United States Code of Federal Regulations and other applicable regulations, and governmental laws. Distributor shall also ensure that its contract vendors maintain a quality system in compliance with current Title 21, United States Code of Federal Regulations and other applicable regulations, and governmental laws.

		
	17.2
	Distributor acknowledges that without registering as an out-of-state home medical device retail facility, an out-of-state home medical device retail facility shall not sell or distribute prescription devices in this state through any person or media other than 

[*****] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS AND ASTERISKS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED INFORMATION.

a wholesaler who is licensed pursuant to Chapter 9 (commencing with Section 4000) of Division 2 of the California Business and Professions Code.  
		
	18.0
	ADDITIONAL DISTRIBUTOR REQUIREMENTS

		
	18.1
	Distributor agrees to comply with all applicable laws and regulations. Distributor agrees to obtain the necessary licenses to meet its obligations under this agreement.

		
	18.2
	Records should be accurate, indelible and legible. Entries must be dated and the person performing a documented task must be identified. Records must provide a complete history of the work performed. Products identified in this Quality Agreement are not in conflict with the laws of the importing country.

[END OF SCHEDULE 5]

[*****] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS AND ASTERISKS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED INFORMATION.

		
	8.
	All other terms and conditions of the Agreement that are not modified or amended pursuant to this Amendment Number Three shall remain in full force and effect and unaffected hereby. This Amendment Number Three may be executed in two (2) or more counterparts, each of which shall be deemed an original, but together shall constitute one and the same instrument.   

[SIGNATURE PAGE FOLLOWS]

[*****] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS AND ASTERISKS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED INFORMATION.

IN WITNESS WHEREOF, authorized representatives of the parties have executed this Amendment Number Two as of date first set out above.

Signed by:    /s/ Jess Roper            
Jess Roper
Title:      V.P. and Chief Financial Officer

for and on behalf of
DexCom, Inc.

Signed by:            /s/ Marc Cohen    
Name: 
Title:          

for and on behalf of 
_______Byram___________________

[*****] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS AND ASTERISKS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED INFORMATION.

Amendment Number Four to Non-Exclusive Distribution Agreement

This Amendment Number Four to the Non-Exclusive Distribution Agreement (“Amendment Number Two”) is made as of this 1 day of November, 2013, by and between DexCom, Inc., a Delaware corporation, with a principal place of business at 6340 Sequence Drive, San Diego, California 92121 (the "Company") and Byram Healthcare and all subsidiaries, a new Jersey corporation with offices located at 120 Bloomingdale Road, Suite 301, White Plains, NY (the “Distributor”). 

WITNESSETH

WHEREAS, Company and Distributor previously entered into a Non-Exclusive Distribution Agreement, effective October 12, 2009, as amended on September 30, 2010, and October 11, 2011, November 14, 2012, and pursuant to the consent to the assignment of the Non-Exclusive Distribution Agreement to Byram Healthcare dated May 2, 2012 (the “Agreement”). 

WHEREAS, Company and Distributor wish to amend the Agreement as set forth herein in accordance with Section 2.2 and 17.10 of the Agreement. 

THEREFORE, Company and Distributor agree as follows:  

 1.  SECTION 2.  Section 2.2 is amended and restated in its entirety as follows:

2.2    New products may be added to Schedule 1 and included within the scope of the Agreement at the sole and exclusive discretion of the Company.  Notice for new products shall be deemed duly given if sent by prepaid mail, addressed to the party at the address set forth at the beginning of this Agreement, or to such other address as the parties may have furnished each other in writing.  In addition, the 

[*****] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS AND ASTERISKS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED INFORMATION.

Company may amend the pricing set forth on Schedule 1 with [****] advance notice provided to Distributor.

REST OF PAGE INTENTIONALLY LEFT BLANK

2.    SCHEDULE 1.  Schedule 1 is amended to include the following Products:  

Dexcom G4 Platinum - Pediatric
 
	
			
	Product
	Description
	Transfer Price*

	STK-KD-001
	Dexcom G4 PLATINUM Pediatric Receiver Kit – BLK
	[****]

	STK-KD-PNK
	Dexcom G4 PLATINUM Pediatric Receiver Kit – PNK
	[****]

	STK-KD-BLU
	Dexcom G4 PLATINUM Pediatric Receiver Kit – BLU
	[****]

       
3.      SCHEDULE 5.  Schedule 5 is amended and restated in its entirety as follows:  

[*****] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS AND ASTERISKS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED INFORMATION.

SCHEDULE 5

Quality Agreement
		
	1.0
	SCOPE

		
	1.1
	This Quality Agreement (the “Quality Agreement”) is incorporated within the Distribution Agreement dated October 12, 2009, as amended on September 30, 2010, and October 11, 2011, November 14, 2012, and pursuant to the consent to the assignment of the Non-Exclusive Distribution Agreement to Byram Healthcare dated May 2, 2012 (the “Agreement”) between Distributor and Company pertaining to the distribution and sale of Products.  Capitalized terms not otherwise defined herein shall have the meaning assigned to them in the Agreement.

		
	1.2
	This Quality Agreement shall be effective on the Effective Date and shall remain in effect until the Agreement expires, is terminated or the Quality Agreement is modified.

		
	2.0
	DEFINITIONS / ACRONYMS

		
	2.1
	“Applicable Documents”:  Documents used to develop a specific document (i.e. standards, regulations) and documents referenced in the text of the specific document.

		
	2.2
	"Government Agency" means any body which has the authority to act on behalf of the government of the Union or State to ensure that the requirements of all laws applicable to the Products and Distributor are carried out and adhered to in the State.

		
	2.3
	"Customer Complaint" means any written, electronic or oral communication that alleges deficiencies related to the identity, quality, durability, reliability, safety or performance of a medical device that has been placed on the market.

		
	2.4
	“CGM”: Continuous Glucose Monitoring.

		
	2.5
	“Correction” means repair, modification, adjustment, relabeling, destruction, or inspection (including patient monitoring) of a product without its physical removal to some other location.

		
	2.6
	“Document” means any information, either written or stored electronically, including specifications, procedures, standards, methods, instructions, plans, files, forms, notes, reviews, analyses, and reports.

		
	2.7
	“Government Agency” means a federal (e.g. FDA) or state (Health and Human Services Food and Drug Branch) organization that has the power to provide services for conformity assessment on the conditions set out in the Federal Food, Drug, and Cosmetic Act (FD&C Act) and United States Code (U.S.C) as part for the sale of medical device products. This normally means assessing the manufacturers conformity to the essential requirements listed in each directive. 

		
	2.8
	 “Lot” or “Batch” means one or more components or finished devices that consist of a single type, model, class, size, composition, or software version that are manufactured under essentially the same conditions and that are intended to have uniform characteristics and quality within specified limits.

[*****] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS AND ASTERISKS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED INFORMATION.

		
	2.9
	“Label” means a display of written, printed, or graphic matter upon the immediate container of any article.  Any word, statement, or other information appearing on the immediate container must also appear “on the outside container or wrapper, if any there be, of the retain package of such article, or is easily legible through the outside container of wrapper.”

		
	2.10
	“Labeling” means any  Labels and other written, printed, or graphic matter (1) upon any article or any of its containers or wrappers, or (2) displaying such article” at any time while a device is held for sale after shipment or delivery for shipment in interstate commerce.

		
	2.11
	 “Quality Records” means Documents containing recorded information, regardless of the medium or characteristic, which demonstrate the effectiveness of the quality management system and that provide evidence that products meet regulatory requirements and comply with specified product requirements.

		
	2.12
	“Removal” means the physical removal of a device from its point of use to some other location for repair, modification, adjustment, relabeling, destruction, or inspection.

		
	2.13
	“Stock Recovery” means the correction or removal of a device that has not been marketed or that has not left the direct control of the manufacturer, i.e., the device is located on the premises owned, or under the control of, the manufacturer, and no portion of the lot, model, code, or other relevant unit involved in the corrective or removal action has been released for sale or use.

		
	2.14
	"Recall" means when there is a risk of death or serious deterioration to the state of health, the return of a medical device to the supplier, its modification by the supplier at the site of installation, its exchange or its destruction, in accordance with the instructions contained in the advisory notice.

		
	2.15
	"Medical Device Reporting System" is a system of incident reporting to the Federal Food and Drug Administration (FDA), for all medical devices which are approved for inter-state commerce, where such incidents lead to corrective action relevant to medical devices.  Medical Device Reporting Systems maintained by the Distributor shall comply with all applicable laws, the rules and regulations promulgated by the Federal or any State. This system is intended to allow data to be correlated between the FDA and manufactures to improve the protection of health and safety of patients, users and others by reducing the likelihood of the same type of adverse incident being repeated in different places at different times. 

		
	3.0
	PROCESS CONTROLS

		
	3.1
	Both parties shall be responsible for all process control activities relative to the Products, including but not limited to, assurance of receipt, identification, traceability, storage, handling, inventory control, contamination control, complaint handling and trending and process validations, as required by Title 21 of United States Code of Federal Regulations, and other applicable regulations, and governmental laws.

		
	3.2
	Both parties shall maintain appropriate documented procedures.

		
	3.3
	Company shall provide evidence that packaging containers maintain the integrity, quality, function, and sterility of the product for the entire shelf life, and not produce toxic residues during storage.  Packaging must prevent or indicate the occurrence of tampering.

[*****] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS AND ASTERISKS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED INFORMATION.

		
	4.0
	TRAINING AND DOCUMENT CHANGE CONTROL

		
	4.1
	Distributor shall be responsible for managing an effective employee training program and document change control system relative to the receipt, identification, traceability, storage, handling, inventory control, contamination control and complaint handling and trending at the location of Distributor and its third party suppliers.

		
	4.2
	Distributor must train its employees to perform their job function and to this Quality Agreement as required.

		
	5.0
	VALIDATION

		
	5.1
	Distributor shall be responsible for managing qualified processes and systems as required of suppliers (e.g. computer system) by law.

		
	5.2
	Both parties shall be responsible for managing an effective product and process validation system relative to the distribution of the Products at the location of the Distributor and its third party suppliers.

		
	5.3
	Both parties shall develop and implement validation or qualification protocols for significant processes, equipment, and computer systems.

		
	5.4
	Company shall be responsible for managing an effective product and process validation system relative to the manufacture of the Products at the location of the Company and its third party suppliers.

		
	6.0
	DISTRIBUTION AND HANDLING

		
	6.1
	Products shipped by the Distributor must be shipped using documented procedures for the handling, storage, packaging, preservation, and delivery of the Products.  

		
	6.2
	Distributor shall deliver Products to its customers using documented procedures for handling, storage, packing, preservation, and delivery of the Products.

		
	6.3
	Disposables must have at least three months of expiration dating left, unless specific variance by lot number has been agreed to by both parties, before being shipped to any end-user customer.  

		
	6.4
	The Distributor will not modify any product packaging that it receives from the Company.  Shipping containers shall be validated to ensure that the safety and integrity of the Product is maintained during transit, including shipping methods that conform with the Product’s acceptable temperature and humidity ranges.

		
	6.5
	Distributor must maintain storage & handling as follows:

Seven Plus Product
	
			
	Product Name
	Storage Temperature
	Humidity

	Sensor
	2-25°C (36-77°F)
	N/A

	Transmitter
	0-45°C (32-113°F)
	Max 95% Relative

	Receiver
	0-45°C (32-113°F)
	10-85% Relative

    

[*****] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS AND ASTERISKS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED INFORMATION.

G4 Platinum Product
	
			
	Product Name
	Storage Temperature
	Humidity

	Sensor
	2-25°C (36-77°F)
	0-95% Relative

	Transmitter
	0-45°C (32-113°F)
	10-95% Relative

	Receiver
	0-45°C (32-113°F)
	10-95% Relative

G4 Platinum Product - Pediatric
	
			
	Product Name
	Storage Temperature
	Humidity

	Sensor
	2-25°C (36-77°F)
	0-95% Relative

	Transmitter
	0-45°C (32-113°F)
	10-95% Relative

	Receiver
	0-45°C (32-113°F)
	10-95% Relative

		
	7.0
	LOT TRACEABILITY

		
	7.1
	Distributor shall establish and maintain procedures for identifying the Products by suitable means from receipt and during all stages of production and delivery.  This shall include procedures to provide full lot traceability for each unit, lot, or batch of finished Products during all stages of production and delivery to the Distributor.  

		
	7.2
	Distributor shall establish and maintain procedures to provide traceability to the first consignee.

		
	7.3
	Distributor shall establish and maintain procedures to provide traceability to the end user.

		
	7.4
	Both parties shall use reasonable efforts to assist the other in maintaining respective lot traceability.

		
	7.5
	Both parties are required to track the following information detailed in the table to the end user. 

		
	8.0
	Seven Plus Product

[*****] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS AND ASTERISKS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED INFORMATION.

	
			
	Product
	Description
	Lot traceability Tracking Requirement

	STK-7U-030
	SEVEN PLUS System Kit
	Lot Number identified on the box

	STS-7K-041
	SEVEN Sensors (package of one (1) or four (4))
	Lot Number identified on the box

	STR-7U- 030
	SEVEN PLUS Replacement Receiver
	Lot Number identified on the box

	STT-7U- 030
	SEVEN PLUS Replacement Transmitter
	Lot Number identified on the box

		
	9.0
	G4 Platinum Product

	
			
	Product
	Description
	Lot traceability Tracking Requirement

	STK-GL-001
	G4 Platinum Receiver Kit – BLK
	Lot Number identified on the box

	STK-GL-PNK
	G4 Platinum Receiver Kit – PNK
	Lot Number identified on the box

	STK-GL-BLU
	G4 Platinum Receiver Kit – BLU
	Lot Number identified on the box

	STT-GL-003
	G4 Transmitter Kit
	Lot Number identified on the box

	STR-GL-001
	G4 Platinum Replacement Receiver Kit – BLK
	Lot Number identified on the box

	STR-GL-PNK
	G4 Platinum Replacement Receiver Kit – PNK
	Lot Number identified on the box

	STR-GL-BLU
	G4 Platinum Replacement Receiver Kit – BLU
	Lot Number identified on the box

	STS-GL-011
	G4 Platinum Sensors Kit (package of one (1))
	Lot Number identified on the box

	STS-GL-041
	G4 Platinum Sensors Kit (package of four (4))
	Lot Number identified on the box

		
	10.0
	G4 Platinum Product - Pediatric

[*****] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS AND ASTERISKS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED INFORMATION.

	
			
	Product
	Description
	Lot traceability Tracking Requirement

	STK-KD-001
	G4 Platinum Pediatric Receiver Kit – BLK
	Lot Number identified on the box

	STK-KD-PNK
	G4 Platinum Pediatric Receiver Kit – PNK
	Lot Number identified on the box

	STK-KD-BLU
	G4 Platinum Pediatric Receiver Kit – BLU
	Lot Number identified on the box

	STT-GL-003
	G4 Transmitter Kit
	Lot Number identified on the box

	STR-KD-001
	G4 Platinum Replacement Receiver Kit – BLK
	Lot Number identified on the box

	STR-KD-PNK
	G4 Platinum Replacement Receiver Kit – PNK
	Lot Number identified on the box

	STR-KD-BLU
	G4 Platinum Replacement Receiver Kit – BLU
	Lot Number identified on the box

	STS-GL-011
	G4 Platinum Sensors Kit (package of one (1))
	Lot Number identified on the box

	STS-GL-041
	G4 Platinum Sensors Kit (package of four (4))
	Lot Number identified on the box

		
	11.0
	PACKAGING AND LABELING

		
	11.1
	Company shall provide packaging and labeling specifications that call out clear labeling requirements. 

		
	11.2
	Company shall ensure that the labels, inserts and accompanying documentation satisfy the requirements of the applicable regulations.

		
	11.3
	Distributor shall not modify the labels, primary or secondary packaging, inserts or accompanying documentation without the written approval of the Company.

		
	12.0
	 FINISHED PRODUCT NON-CONFORMANCES

		
	12.1
	Any nonconforming finished product requires written approval from Company’s Quality Assurance before shipment to any Customer by Distributor. 

[*****] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS AND ASTERISKS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED INFORMATION.

		
	13.0
	COMPLAINT HANDLING AND REPORTING

		
	13.1
	Distributor shall be responsible for the establishment and maintenance of a system for handling all Tier I Complaints pertaining to Products distributed under the Agreement.  "Complaint" means any written, electronic, telephone call and/or oral communication that alleges deficiencies related to the identity, quality, durability, reliability, safety, effectiveness, or performance of a device after it is released to distribution.  A complaint is any indication of the failure of a device to meet customer or user expectations for quality or to meet performance specifications.  A “Tier I Complaint” includes complaints that pertain to the purchase, payment, billing, delivery, packaging and customer service.  This system shall include receipt, review, corrective/preventative action and maintenance of files.  Distributor will not perform any Tier II Complaint Handling, as defined below.  

		
	13.2
	Company shall be responsible for the establishment and maintenance of a system for handling Tier II Complaints pertaining to Products distributed under the Agreement.  A “Tier II Complaint” includes complaints that pertain to product functionality, trouble shooting, or adverse events.  This system shall include receipt, review, investigation, corrective/preventative action and maintenance of files.  It shall also include adverse event reporting to the appropriate governmental authorities as required by regulations in the applicable jurisdictions.

		
	13.3
	Company shall notify Distributor in writing of legal and regulatory matters relating to the Products, including:

		
	13.3.1
	Any regulatory actions by governmental authorities (e.g., inspection citations, warning letters, or other non-conformance notices).

		
	13.3.2
	Regulatory enforcement actions such as injunctions or seizures.

		
	13.3.3
	FDA registration activity (e.g., non-conformance notices, hold points).

		
	13.3.4
	Complaints received from Customers within the Territory that have not been processed through the Company’s complaint handling system.

		
	13.3.5
	Adverse incidents relating to customers within the Territory (e.g., MDR’s.).

		
	14.4
	Distributor shall notify Company in writing of the following:

		
	14.4.1
	Any serious regulatory action relating to the Products.

		
	14.4.2
	Tier I Complaints regarding Products or Instruments. Distributor shall code, trend and report monthly all phone call inquiries and Tier I Complaint data pertaining to Products.  

		
	14.4.3
	If an adverse incident is received that may be subject to FDA’s Medical Device Reporting regulation that pertain to Products and Instruments, then Distributor shall notify Company  no later than 24 hours following Distributor’s initial receipt of the adverse event.

		
	14.4.4
	  Distributor shall forward all complaints pertaining to Products and Instruments to Company no later than 5 working days following Distributor’s initial receipt of the complaint.

		
	14.0
	FIELD ACTIONS

		
	14.1
	The Company will be responsible for the initiation of any recalls or other field actions related to the Products.

[*****] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS AND ASTERISKS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED INFORMATION.

		
	14.2
	Both parties will comply with recalls or general corrective actions, provided such recalls or general corrective actions do not, in the opinion of Company violate or cause Company to violate the laws of any jurisdiction affected by the recalls or corrective action.

		
	14.3
	If Distributor and Company do not agree on a course of action, Company may initiate field actions related to the Products, but may not use field action to cause Distributor to lose Customers. 

		
	15.0
	AUDITS

		
	15.1
	  Company shall have the right to conduct audits of Distributor’s facilities and operations during normal business hours at its own expense and upon thirty (30) days notice to Distributor in order to assess compliance with all applicable regulations, procedures and this Quality Agreement.  Any such audits will be conducted by a national “big four” independent accounting firm (or other independent accounting firm whose audit department is a separate stand alone function of its business and which possesses liability insurance with coverage of at least [****]), subject to such firm’s execution of a confidentiality agreement in form reasonably acceptable to Distributor. Company shall be permitted to conduct one audit per calendar year or more frequently in the instance there exists a material difference between the inventory records of Distributor and Company.

		
	16.0
	RECORD RETENTION

		
	16.1
	Both parties shall retain all sales and medical records as required by law.  

		
	16.2
	Prior to any record destruction pertaining to Company Products and Instruments, the Distributor will notify the Company in writing.  If the record destruction is not approved the Company will assume responsibility of the records.

		
	17.0
	REGULATORY AND REGISTRATION ADMINISTRATION

		
	17.1
	Distributor, at its expense, is responsible for registration responsibilities, and for agreed upon domestic registration costs in accordance with Federal and State regulations.  Distributor shall provide sufficient data and information to support domestic registrations.

		
	17.2
	Company, at its expense, is responsible for registration responsibilities, and for agreed upon registration costs of Products in the Territory.  Company shall provide sufficient data and information to support such registrations.

		
	18.0
	QUALITY SYSTEM COMPLIANCE

		
	18.1
	Distributor shall establish and maintain a quality system in compliance with Title 21, United States Code of Federal Regulations and other applicable regulations, and governmental laws. Distributor shall also ensure that its contract vendors maintain a quality system in compliance with current Title 21, United States Code of Federal Regulations and other applicable regulations, and governmental laws.

		
	18.2
	Distributor acknowledges that without registering as an out-of-state home medical device retail facility, an out-of-state home medical device retail facility shall not sell or distribute prescription devices in this state through any person or media other than 

[*****] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS AND ASTERISKS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED INFORMATION.

a wholesaler who is licensed pursuant to Chapter 9 (commencing with Section 4000) of Division 2 of the California Business and Professions Code.  
		
	19.0
	ADDITIONAL DISTRIBUTOR REQUIREMENTS

		
	19.1
	Distributor agrees to comply with all applicable laws and regulations. Distributor agrees to obtain the necessary licenses to meet its obligations under this agreement.

		
	19.2
	Records should be accurate, indelible and legible. Entries must be dated and the person performing a documented task must be identified. Records must provide a complete history of the work performed. Products identified in this Quality Agreement are not in conflict with the laws of the importing country.

[*****] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS AND ASTERISKS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED INFORMATION.

4.   All other terms and conditions of the Agreement shall remain in full force and effect.  

IN WITNESS WHEREOF, authorized representatives of the parties have executed this Amendment Number Two as of date first set out above.

Signed by:    /s/ Jess Roper            
Jess Roper
Title:      V.P. and Chief Financial Officer

for and on behalf of
DexCom, Inc.

Signed by:            /s/ Marc Cohen    
Name: 
Title:          

for and on behalf of 
______________Byram____________

[*****] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS AND ASTERISKS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED INFORMATION.VVC 10K 2013 Exhibit 10.14

Exhibit 10.14

VECTREN CORPORATION
AT RISK COMPENSATION PLAN 
STOCK UNIT AWARDS
 AWARD AGREEMENT
(OFFICER)

	
			
	Name of Grantee:
	 
	No. of Units:    
    

	Date of Grant:
	January 17, 2014
	 

__________ (“Grantee”) is hereby granted on January 17, 2014 (the “Grant Date”) under Section 7.4 of the Vectren Corporation At Risk Compensation Plan (the “Plan”) a grant of _____ Stock Unit Awards on the following terms and conditions:
1.    Restriction.

             (A)      Value of the Stock Unit Award.  Subject to approval by the Compensation and Benefits committee (Committee) of the Board of Directors (Board) of Vectren Corporation (Company), as of the date of the lifting of the restrictions or no later than sixty days after that date or if subject to 1.(C)(ii) no later than two and one half months after the end of the performance period, the Grantee shall be paid, for each Stock Unit Award, in cash, the value of one share of Common Stock determined by calculating the average of the closing price of the Common Stock on the New York Stock Exchange for the three consecutive trading days immediately preceding December 25, 2017, or if the lifting of restrictions occurs prior to December 25, 2017, the Fair Market Value of one share of Common Stock on the date the restrictions lapse; provided, however, if the restrictions are being lifted as of December 31, 2017, and the Grantee is not then in compliance with the share ownership guidelines established by the Company's Board, at that time the value of each Stock Unit Award shall be paid to the Grantee in one unrestricted share of the Company's common stock. The determination of compliance will be made by valuing the Grantee's ownership interest by averaging the high and low prices of a share of the Company's common stock during the preceding month of November and comparing the resulting amount of ownership interest against the then applicable share ownership guideline.  
 
		
	(B)
	Restricted Period.  Except as otherwise provided pursuant to or in accordance with the terms and provisions of this Agreement or the Plan, the Stock Unit Awards shall not be sold, exchanged, assigned, transferred or permitted to be transferred, voluntarily, involuntarily, or by operation of law, delivered, encumbered, discounted, pledged, hypothecated, or otherwise disposed of during the “Restricted Period,” which shall, with respect to each Stock Unit Award commence on the Grant Date and, except as otherwise provided in this Agreement or the Plan, end on December 31, 2017.

		
	(i)
	Final Measurement of the Stock Unit Award.  Except as provided in this Agreement or the Plan, including Section 7.4(b)(i) and Article X, the lifting of the transferability restrictions and the forfeitability provisions shall be dependent on (1) the shareholder value performance (as measured by total shareholder return or TSR) of the underlying Stock during the TSR Measuring Period (January 1, 2014 through December 31, 2016), (2) the earned return on equity (ROE) of Vectren Corporation (Company) for the twelve months ended December 31, 2016 (the ROE Measuring Period) relative to the performance metrics established by the Compensation and Benefits committee (Committee), and (3) the continued employment of the Grantee until December 31, 2017.

(a) Total Shareholder Return.  Fifty percent of the final amount of the Stock Unit Award shall be determined based upon the Company's TSR performance relative to the TSR of 

the companies within the peer group established by the Committee and determined in accordance with the rules established by the Committee, all of which are incorporated herein by reference.  In addition to the information that is incorporated herein by reference, the TSR performance conditions will operate in the following manner.  For the TSR Measuring Period, the shareholder value performance of the Company shall be compared with the shareholder value performance of the group of comparable companies designated by the Committee.  TSR performance shall be determined separately for Company and for each company included as part of the group of comparable companies by dividing:
		
	(1)
	the difference between

(A)    the sum of (A) the average for each peer group company of the monthly averages of the highest and lowest trading price of the common stock of such company for the last twelve (12) months of the TSR Measuring Period, and (B) any dividends, cash or stock, paid per share with respect to such company's common stock during the TSR Measuring Period, and
(B)    the average for each peer group company of the monthly averages of the highest and lowest trading price of the common stock of such company for the twelve (12) months immediately preceding the TSR Measuring Period,
by
		
	(2)
	(B) above; provided, however, that if during the period in which shareholder value performance is determined, Company or any of the comparable companies incurs a change in its outstanding shares because of a stock dividend, stock split, merger, consolidation, stock rights plan or exchange of shares or other similar corporate change, the Committee shall appropriately modify the above shareholder value performance determination to reflect such change in capitalization.  

Pursuant to the TSR Performance Schedule applicable to this Grant and established by the Committee, depending on how Company performs in relationship to the group of comparable companies with respect to its TSR performance, fifty percent of the Stock Unit Award will be subject to adjustment at the end of the TSR Measuring Period.
(b) Earned Return on Equity.  Fifty percent of the final amount of the Stock Unit Award shall be determined based upon the Company's earned ROE for the twelve months ended December 31, 2016 relative to the metrics established by the Committee and determined in accordance with the rules established by the Committee, all of which are incorporated herein by reference.   

		
	(ii)
	Lifting of Restrictions.  The restrictions applicable to the Stock Unit Awards held by the Grantee at the end of the TSR and ROE Measuring Periods (after the completion of the adjustments in the number of Stock Unit Awards by reason of the computations called for by the (A) the TSR Performance Schedule, and (B) the ROE metrics) (January 1, 2014 through December 31, 2016 is the “Performance Period”) shall be lifted in whole as of December 31, 2017; provided, however, that except as provided in the Plan, which directs, under certain conditions, that the restrictions shall be lifted earlier:  (a) the restrictions shall be lifted on December 31, 2017 only if the Grantee is still employed by a Participating Company on that date, and, subject to the terms of this Agreement and the Plan, (b) if the Grantee ceases to be employed by a Participating Company before the restrictions lapse on any Stock Unit Awards held by him or her, the Stock Unit Awards still subject to restrictions shall be immediately forfeited.  

		
	(iii)
	Continued Service As A Director.  If the Grantee (a) whose employment is terminated with a Participating Company for any reason and (b) who is a director of Company immediately prior to the Grantee's termination of employment continues to serve Company as a director following the Grantee's termination of employment, the Committee shall have the complete and sole discretion to deem the Grantee's employment with the Participating Company as continuing for 

purposes of this grant of Stock Unit Awards for all or a portion of the period in which the Grantee continuously serves as a member of the Board.
		
	(C)
	Disability, Death or Retirement.  In the event of the Grantee's death, Disability, or Retirement the following shall apply: 

 
		
	(i)
	If such event occurs after the end of the Performance Period but before the end of the Restriction Period, the restrictions on the Stock Unit Awards shall be immediately removed; 

 
		
	(ii)
	In the event of the Grantee's Disability or Retirement before the Performance Period has ended, the restrictions on the Stock Unit Awards shall be removed upon (a) expiration of the Performance Period, and (b) certification by the Committee of the Company's performance under the Total Shareholder Return and Return on Equity metrics applicable to this Grant. The number of Stock Unit Awards the Grantee shall be entitled to, if any, shall equal (i) the number of Stock Unit Awards, if any, the Grantee would otherwise be entitled to had the individual been an active Participant at the end of the Performance Period (i.e., as adjusted or forfeited based on the Performance Criteria) multiplied by (ii) the portion of Performance Period the Grantee was an active Participant hereunder;

 
		
	(iii)
	In the event of the Grantee's death before the Performance Period has ended, the restrictions on the Stock Unit Awards shall be removed upon the Grantee's date of death, and the number of Stock Unit Awards the Grantee shall be entitled to, if any, shall equal the number of Stock Unit Awards contingently granted hereunder without any further adjustment; and

 
		
	(iv) 
	Notwithstanding the terms of the Plan and any other provision of this Agreement, in the event of the Grantee's Disability or Retirement prior to the end of the Performance Period, the Committee may, but shall not be obligated to, permit the Grantee to receive the number of Stock Unit Awards, if any, that the Grantee would otherwise be entitled to had the Grantee been an active employee at the end of the Performance Period (as adjusted or forfeited based on the Performance Criteria) without any reduction for the time the Grantee was not an active employee during the Performance Period.

		
	2.
	Capitalization Changes.  Prior to the lifting of restrictions, in the event of a change in the Company's outstanding shares by reason of a stock dividend, stock split, merger, consolidation, stock rights plan or exchange of shares or other similar corporate change, the Committee shall make appropriate adjustments in the number of Stock Unit Awards granted hereunder.

		
	3.
	Dividends.  Each time a dividend is paid on the Company's common stock, the amount of the dividend, multiplied by the number of Stock Unit Awards set forth herein, as adjusted by the receipt of additional Stock Unit Awards under this paragraph, shall be divided by the closing price of the Company's common stock on the dividend payment date and such resulting number shall be added to the number of Stock Unit Awards granted to the Grantee under this Agreement.

		
	4.
	Investment Representation.  By executing this Agreement, Grantee represents that the Stock Unit Award is being held in good faith for investment purposes only and not with a view to, or for sale in connection with, any distribution thereof, and that any Stock Unit Award Grantee or Grantee's legal representatives acquire pursuant to this award will be acquired by them in good faith for investment purposes and not with a view to, or for sale in connection with, any distribution thereof.

5.       Clawback Policy.  By executing this Agreement and receiving the Grant provided for hereunder Grantee acknowledges that under the Dodd Frank Act Wall Street Reform and Consumer Protection Act (“Act”) Company will be obligated to adopt a clawback policy that may require, under certain circumstances, the recoupment of compensation previously paid to designated individuals, including equity based compensation. Grantee further acknowledges that at the time of this Grant there is uncertainty regarding the form of such a required clawback policy and until the federal government provides further guidance in this area Company is not able to adopt its final policy under the Act. Grantee hereby agrees that during the pendency of this Grant if and when Company's required clawback policy is finalized, to the extent that policy is determined to apply to this Grant, which determination shall be made by the Committee, in their reasonable judgment, at the time the required policy is finalized by the Committee, the provisions of that policy shall be incorporated herein by 

reference and this Grant shall be subject to that policy as if it was in effect as of the date hereof. Grantee further acknowledges that pending the finalization of that policy, this grant shall be subject to any interim policy that may be effective during the pendency hereof including the policy adopted on March 2, 2011, as the same may be amended from time to time.       
		
	6.
	Continued Employment.  Nothing in this Agreement shall restrict the right of Vectren Corporation or its affiliates to terminate Grantee's employment or status as a consultant at any time with or without cause.

		
	7.
	The Plan.  This grant is subject to all the terms, provisions and conditions of the Plan, which is incorporated herein by reference, including the defined terms not otherwise defined herein, and to such regulations as may from time to time be adopted by the Committee.  In the event of any conflict between the provisions of the Plan and the provisions of this Agreement, the terms, conditions and provisions of the Plan shall control, and this Agreement shall be deemed to be modified accordingly.

		
	9.
	Withholding.  Vectren shall withhold all applicable taxes required by law from all amounts paid in satisfaction of the award.  

		
	10.
	Notices.  All notices by the Grantee or his or her assigns to Vectren shall be addressed to Vectren Corporation, One Vectren Square, Evansville, Indiana  47708, Attention:  Corporate Secretary, or such other address as Vectren may, from time to time, specify.  All notices by Vectren to the Grantee shall be addressed to the Grantee at their current work location at Vectren or, if they are no longer employed by Vectren, at the address on file for the Grantee with the Human Resources department of Vectren.  

VECTREN CORPORATION

By:    _________________________________
Its:    A Duly Authorized Signatory on behalf of the Compensation and Benefits Committee    

Accepted as of the date first above written

______________________________________ Grantee

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00226-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00226-of-00352.parquet"}]]